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ABSTRACT 
Investigation of the biological basis of anxiety is ham-
pered by the lack of an appropriate animal model for research 
purposes. There are no known drugs that cause anxiety in 
laboratory animals. Pentylenetetrazol (PTZ) produces intense 
anxiety in human volunteers (Rodin, 1958; Rodin and Calhoun, 
1970). Therefore, it was the major objective of this disser-
tation to test the hypothesis that the discriminative stimu-
lus produced by PTZ in the rat was related to its anxiogenic 
action in man. It was also an objective to suggest the neuro-
chemical basis for the discriminative stimulus property of 
PTZ through appropriate drug interactions. In an operant pro-
cedure of lever pressing on a FR 10 schedule of food rein-
forcement, male hooded rats were trained to respond with a 
lever on one side of a food cup 15 min following a 20 mg/kg 
PTZ injection and to respond with a lever on the alternate 
side 15 min following a 1 ml/kg saline injection. All of 
the rats learned this discrimination reliably in a mean of 30 
training sessions. The discriminative stimulus produced by 
PTZ was dose- and time-dependent. The anxiogenic stimulants 
cocaine, R05-3663 and strychnine generalized to the PTZ dis-
criminative stimulus whereas yohimbine partially generalized. 
The discriminative stimulus produced by cocaine, R05-3663 
and yohimbine was antagonized by the anxiolytic drug, diazepam. 
The discriminative stimulus produced by cocaine was not antag-
onized by haloperidol. The non-anxiogenic psychomotor stimu-
lants ~-amphetamine, methylphenidate or caffeine did not gen-
eralize to ~he PTZ discriminative stimulus. Bemegride was 
the only convulsant drug tested that generalized to the PTZ 
discriminative stimulus. Picrotoxin and 3-mercaptopropionic 
partially, but not significantly, generalized to the PTZ dis-
criminative stimulus but bicuculline, garnma-hydroxybutyrate 
or nicotine did not generalize. The PTZ discriminative stim-
ulus was dose-dependently antagonized by benzodiazepine-type, 
barbiturate-type, propanediol carbamate-type anxiolytics as 
well as valproic acid. Tolerance did not develop to antago-
nism of the PTZ of discriminative stimulus by diazepam or 
chlordiazepoxide. The discriminative stiIT'ulus produced by 
PTZ was not antagonized by an anticonvulsant or other central 
nervous system depressants that are not anxiolytics. There 
was a significant correlation between the potency of drugs 
effective in antagonizing the PTZ discriminative stimulus 
and their effective doses in a conflict test of anxiety as 
well as their clinically effective doses. The GABA antago-
nist ROS-3663 generalized to the PTZ discriminative stimulus 
whereas picrotoxin and 3-mercaptopropionic acid partially 
generalized. The PTZ discriminative stimulus was antagonized 
by the GABA mimetic, valproic acid. The glycine antagonist, 
strychnine, generalized to the PTZ discriminative stimulus. 
Neither acetylcholine nor serotonin agonists or antagonists 
generalized to or antagonized the PTZ discriminative stimulus. 
The catecholamine agonist, cocaine, generalized to the PTZ 
discri~inative stimulus whereas yohimbine and apomorphine par-
tially generalized. However, neither a-amphetamine nor methyl-
phenidate generalized to the PTZ discriminative stimulus and 
catecholamine receptor antagonists did not antagonize the PTZ 
discriminative stimulus. Generalization to the PTZ discrimi-
native stimulus by anxiogenic drugs and lack of generalization 
by non-anxiogenic psychomotor stimulants or convulsants as 
well as antagonism of the PTZ discriminative stimulus by anxi-
olytics but not non-anxiolytic anticonvulsant or depressants 
supports the hypothesis that the discriminative stimulus pro-
duced by PTZ in the rat is related to its anxiogenic action 
in man. Generalization to the PTZ discriminative stimulus by 
GABA antagonists and antagonism by GABA agonists but lack of 
generalization to or antagonism by drugs affecting other neu-
rotransmitter systems suggests that the PTZ discriminative 
stimulus might be ·mediated through decreased GABA neuronal ac-
tivity. 
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INTRODUCTION 
Anxiety is an unpleasant emotion for which millions of 
patients visit physicians each year seeking relief (Rickels 
et al., 1978). Anxiety can be defined as that experience or 
feeling of an unpleasantness or impending doom (Matz and 
Nash, 1979). 
Although we suffer from and can define anxiety we do not 
understand its biological basis. This is partly because in-
vestigations of the biological basis of anxiety have been 
hampered by the lack of an appropriate animal model for re-
search purposes. Presently, conflict paradigms such as those 
described by Geller and Seifter (1962) and Howard and Pollard 
(1977) are believed to provide the best animal models of an-
xiety. These procedures have been used to investigate the 
biological basis of anxiety as well as the neurochemical mech-
anisms underlying the anxiolytic action of anti-anxiety drugs 
(for reviews see Sepinwall and Cook, 19 7 8; Lippa ·et al., 19 79) . 
However, with regard to elucidating the biological basis of 
anxiety these studies have not met with great success. In 
addition, conflict procedures are not without methodological 
problems that make interpretation of results difficult 
(Howard and Pollard, 1977) . Therefore, a more appropriate 
animal model to investigate the biological basis of anxiety 
is needed. 
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Pentylenetetrazol (PTZ) has been reported to produce in-
tense anxiety in human volunteers (Rodin, 1958; Rodin and 
Calhou~, 1970). In a personal communication, Rodin wrote 
" ... within a matter of seconds [(after he had had himself in-
jected with the drug by another physician)] I experienced 
catastrophic anxiety ... It was a sense of utter distress and 
impending catastrophe. There is no doubt that this was one 
of the most anxiety producing events of my life." 
Subjective effects of drugs cannot be measured directly 
in laboratory aniITals, however, it is believed that these ef-
fects are reflected in the discriminative stimulus properties 
of drugs in a number of cases (for review see Lal, 1977; 
Schuster and Balster, 1977; Colpaert and Rosecrans, 1978). 
Therefore it was the major objective of this dissertation to 
test the hypothesis that the discriminative stimulus pro-
duced by PTZ in the rat was related to its anxiogenic action 
in humans. It was also an objective to suggest a neurochemi-
cal basis of the discriminative stimulus property of PTZ in 
the rat. 
It was hoped that characterization of the anxiomimetic 
property of PTZ in the rat utilizing the drug discrimination 
paradigm would provide a more appropriate animal model to in-
vestigate the biological basis of anxiety. 
This research problem is of significance because it 
could contribute towards a better understanding of the bio-
logical basis of anxiety which could result in the develop-
ment of better treatments for this unpleasant emotion. 
LITERATURE REVIEW 
BEHAVIORAL AND NEUROCHEMICAL ACTIONS OF PTZ 
A.Behavioral Actions of PTZ 
Most of the research to date on the behavioral actions 
of PTZ have been concerned with the effect of this drug on 
learning and memory. This section of the literature review 
will therefore concentrate on the effect of PTZ on these be-
haviors. 
Facilitation of Learning 
Several investigators have reported that subconvulsive 
doses of PTZ facilitate learning in a variety of experiment-
al situations. Irwin and Benucazizi (1966) found that PTZ 
(1-30 mg/kg, p.o.) significantly facilitated one~trial learn-
ing and memory retention of CF 1 mice in a passive avoidance 
task. This effect occurred whether PTZ was injected before 
or immediately after the training trial and was greater than 
that observed with strychnine or picrotoxin. 
Using a simple Y maze, Hunt and Krivanek (1966) and 
Krivanek and Hunt (1967) reported that post-trial injections 
of PTZ (_20 mg/kg) improved learning of a black-white bright-
ness discrimination. Animals treated with PTZ reached the 
criterion of learning earlier and made fewer errors than did 
saline treated animals. 
4 
Grossman (1969) bilaterally injected PTZ (5-10 ug) di-
rectly into the hippocamus of rats before as well as after 
traini~g to perform a brightness discrimination. PTZ facil-
itated the learning of this discrimination and post-trial in-
jections of PTZ were found to produce a significantly great-
er effect than pre-trial injections. It was suggested that 
PTZ facilitated learning by activating neural pathways con-
cerned with memory consolidation processes. 
Hunt and Bauer (1969) reported that subconvulsive doses 
(7.5-15 mg/kg) of PTZ, when injected immediately or 15 min 
following training of a black-white brightness discrimina-
tion, facilitated learning. Animals retested 24 h after 
training performed significantly better than saline treated 
animals. In a position discrimination task, Hunt and Bauer 
(1969) reported that PTZ (10 mg/kg) maximally facilitated 
learning when injected 10 min after training. 
Bauer (1969) injected subconvulsive doses of PTZ daily 
for 20 days and reported this dosage regimen to facilitate 
learning of a shuttle box avoidance or a brightness discrim-
ination task when testing occurred 24 h after the last PTZ 
injection. Interestingly, Bovet et al. (1966) had reported 
that whereas strychnine or picrotoxin enhanced shuttle avoid-
ance learning, PTZ (5 or 10 mg/kg) did not. Buckholtz (1974) 
also reported that PTZ (20 mg/kg) did not facilitate shuttle 
avoidance learning. Using a wheelturn avoidance procedure, 
Krivanek (1971) reported subconvulsive doses of PTZ facili-
tated learning. 
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For the most part, studies employing subconvulsive doses 
of PTZ demonstrate that this drug facilitates learning. It 
has been suggested that PTZ produces this effect by facili-
tating memory consolidation. 
Impairment of Learning 
An impairment or loss of memory for events preceding a 
trauma is referred to as retrograde amnesia. Whereas subcon-
vulsive doses of PTZ are reported to facilitate learning, 
convulsive doses of this drug produce retrograde amnesia or 
impair learning. 
Palfai and Chillag (1971) reported that a convulsive 
dose (50 mg/kg) of PTZ, when injected up to 20 but not 60 
min after training produced retroqrade ar.mesia in mice for 
a step-through passive avoidance task. The degree to which 
PTZ produced retrograde amnesia was directly related to the 
intensity of the foot shock indicating that the nature of 
the original traumatic experience contributed towards the 
temporal characteristics of the retrograde amnesia. Because 
electroconvulsive shock had previously been reported to pro-
duce retrograde amnesia Palfai and Chillag (1971) suggested 
that a "massive neural explosion" causes retrograde amnesia. 
Palfai and Kurtz (1973) reported that this convulsive 
dose of PTZ injected 15, 30 or 60 min but not 4 hr before a 
single step-through passive avoidance training impaired re-
tention performance 24 h later. Interestingly, when this 
dose of PTZ was injected inunediately after the training trial 
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it did not immediately produce retrograde amnesia, but rather 
the amnesia became apparent 4.5 h following the PTZ injection. 
These data indicate that a convulsive dose of PTZ can affect 
memory for a long (24 h) time after injection. Palfai and 
Kurtz (1973) suggested that PTZ may produce dissociated mem-
ory consolidation and that PTZ did not immediately produce 
amnesia because the drug state in which memory consolidation 
took place was still present when the rats were tested. How-
ever, when the animals were tested 4.5 h after the PTZ injec-
tion a different brain state may have existed that resulted 
in impaired retention. 
Kurtz and Palfai (1973) tested for a dissociated or 
state-dependency hypothesis for the memory impairment pro-
duced by PTZ. Using the step-through passive avoidance task 
(Palfai and Kurtz, 1973), results were suggestive for the 
state-dependency hypothesis but PTZ produced a general de-
pression of activity that may have confounded this interpre-
tation. Therefore, Kurtz and Palfai (1973) used a discrimi-
nated escape paradigm to test for dissociative properties 
of PTZ. When reversal training and testing occurred under 
similar physiological states, i.e., both following PTZ in-
jection (PTZ-PTZ) or both in the non-drug state (saline-
saline), test performance was unimpaired. However, when PTZ 
was injected before reversal training but not before test-
ing (PTZ-Saline) or vice versa (Saline-PTZ) test performance 
was impaired. These data suggest that retrograde amnesia 
produced by a convulsive dose of PTZ was related to its dis-
7 
sociative or state-dependent effects. Furthermore, these data 
suggest the PTZ seizures may interfere with memory retrieval 
rather.than memory consolidation. 
To determine if convulsions were necessary for PTZ to 
produce state-dependent learning, Palfai and Kurtz (1976) 
tested for the ability of a subconvulsive dose (30 mg/kg) of 
PTZ to produce this phenomenon. Unlike the convulsive dose 
of PTZ that produced symmetrical dissociation, the subcon-
vulsive dose produced asymmetrical dissociation, that is, 
whereas training in the non-drug state did transfer to the 
drug state during testing, training in the drug state did 
not transfer to testing in the non-drug state. Electroen-
cephalographic (EEG) changes were still evident at the time 
when training and testing took place after injection of the 
convulsive dose but not the subconvulsive dose. Therefore, 
the EEG correlates could explain the asymmetrical dissoci-
ation produced by the non-convulsive dose of PTZ. 
Whereas it was suggested (Weissman, 1968) that only 
convulsive doses of PTZ produce retrograde amnesia, van 
Buskirk and McGaugh (1974) reported that in Ha/ICR mice sub-
convulsive as well as convulsive doses of PTZ, injected after 
training of a passive avoidance task, impaired retention of 
the task. However, in C57 BL/6J mice convulsive doses of 
PTZ did not impair retention. Not only do these data point 
out species differences with respect to the effect of PTZ in 
producing retrograde amnesia, these data also indicate that 
convulsions are not a prerequisite for PTZ to induce retro-
8 
grade amnesia. The data of Essman (1968) and Vinnitsky and 
Abulzade (1971) was cited by van Buskirk and McGaugh (1979) 
as supporting the suggestion that seizures are not required 
for the retrograde amnesia effect of PTZ. Essman (1968) re-
ported that a post-trial convulsive dose (60 mq/kg) of PTZ 
produce retrograde amnesia even when the convulsions were 
blocked by lidocaine pretreatment. A similar finding was re-
ported by Vinnitsky and Abulzade (1971) using other anes-
thetic agents. However, Palfai and Albula (1976a) criti-
cized the data of Essman (1968), pointing out that lidocaine 
only partially blocked the seizures. Using a passive avoid-
ance conditioning paradigm, Palfai and Albula (1976a) re-
ported that convulsions were necessary for the development 
of PTZ-induced retrograde amnesia. These authors reported 
that subconvulsive doses (10 or 30 mg/kg) of PTZ did not 
produce retrograde amnesia and that animals pretreated with 
pentobarbital to block PTZ convulsions did not show retro-
grade amnesia. 
Convulsive doses of PTZ have also been reported to pro-
duce retrograde amnesia for classically conditioned fear and 
taste aversions. Palfai and Cornell (1968) reported that 
seizures produced by PTZ caused amnesia for classically con-
ditioned fear when PTZ was injected immediately following the 
conditioning trial. Subconvulsant doses of PTZ or convul-
sant doses injected 4 or 24 h (Palfai and Albula, 1976b) af-
ter training did not produce amnesia. Retrograde amnesia 
produced by PTZ was still evident 1 week after PTZ adminis-
9 
tration. Ahlers and Best (1972) reported that convulsions in-
duced by PTZ produced amnesia for a conditioned taste aversion 
to a n?vel taste produced by injections of apomorphine. Mill-
ner and Palfai (1975) injected PTZ (40 mg/kg) 2 min before, 
immediately or 3 min after injection of LiCl and reported con-
ditioned aversion to the taste of saccharin. Kessler and 
Gellhorn (1943) had also reported that a convulsive dose of 
PTZ disrupted conditioned behavior. 
Putney and McCoy (1976) found that a subconvulsive dose 
(10 mg/kg) of PTZ enhanced the ability of subthreshold elec-
troconvulsive (ECS) shock to produce retrograde amnesia. 
Whereas ECS administration alone given 60 min after passive 
avoidance learning did not produce amnesia, injection of PTZ 
plus ECS produced amnesia. 
Possible Chemical Basis of PTZ-Induced Retrograde Amnesia 
Essman (1968) reported that a convulsive dose (60 mg/kg) 
of PTZ injected immediately following a single trial to estab-
lish a passive avoidance response produced retrograde a~ne­
sia for the task but did not significantly change the brain 
ribonucleic acid (RNA) concentration. Therefore whereas the 
amnesia effect of some agents has been attributed to their 
ability to decrease brain RNA (for review see Seiden and 
Dykstra, 1977), retrograde amnesia produced by PTZ could 
not be correlated with a change in brain RNA. 
Palfai et al. (1974) reported a reduction in whole brain 
norepinephrine at 5 min but not one or 24 h after injection 
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of a convulsive dose (50 mg/kg) of PTZ in mice trained in a 
passive avoidance paradigm. Because the time course of ante-
rograde amnesia reported by Palfai and Kurtz (1973) was sim-
ilar to the time course of the brain norepinephrine decrease 
and recovery it was suggested that normal norepinephrine le-
vels in brain during the early phase of memory storage may be 
necessary for retention. However, convulsions produced by 
PTZ have been reported to alter the brain levels of several 
other neurotransmitters (see next section: Neurochemical 
Action of PTZ) therefore these substances must also be looked 
at with respect to their possible involvement in mediating 
the amnestic effect of PTZ before any conclusion can be made 
concerning norepinephrine. 
Iuvone et al. (1977) reported that immediate post-train-
ing administration of subconvulsive (50 mg/kg) or convulsive 
(60 mg/kg) doses of PTZ resulted in significant retention 
deficits on step-through inhibitory avoidance behavior. These 
doses also inhibited the incorporation of 3tt-lysine into 
brain protein during the first 10 min after training and PTZ 
injection. These data suggest a relationship between inhibi-
tion of protein synthesis and PTZ-induced retrograde amnesia. 
Bookin and Pfeifer (1977) injected lysine vasopressin 
(_LVP). one hour prior to the acquisition trial and retention 
trial in a passive avoidance task and reported that LVP fa-
cilitated passive avoidance retention and antagonized amne-
sia for retention of the task produced by PTZ (50 mg/kg). 
Because PTZ has been proposed to exert its amnestic effect 
11 
by interfering with retrieval process (Kurtz and Palfai, 1973) 
it was proposed that LVP may exert its anti-PTZ effect by fa-
cilita~ing retrieval processes or blocking the PTZ-induced 
interference with retrieval. 
PTZ-Induced Amnesia as a Tool to Screen Anti-Petit Mal Drugs 
Clincke and Wauquier (1979) reported that a subconvul-
sive dose (40 mg/kg) of PTZ, injected 30 min before testing, 
impaired retention of behavior in a step-down passive avoid-
ance procedure. Pretreatment, 5 min before PTZ, with the 
anti-petit mal drugs ethosuximide, trimethadione or clonaze-
pam antagonized amnesia produced by PTZ. In contrast drugs 
ineffective against petit mal epilepsy including phenobarbi-
tal, diphenylhydantoin, haloperidol, amphetamine, valproic 
acid or carbamazepine did not antagonize the amnestic effect 
of PTZ. These data suggest that this paradigm might be use-
ful to screen effective anti-petit mal drugs from other anti-
epileptic and nonspecific drugs. 
Conclusion 
In a number of different paradigms subconvulsive dose 
of PTZ injected before or after training of a learning task 
facilitate learning or enhance retention whereas convulsive 
doses of this drug impair retention or produce amnesia. These 
effects are time dependent for the task. The exact mechanism 
for these effects of PTZ are unclear. However, it has been 
suggested that subconvulsive doses may facilitate learning 
12 
by facilitating memory consolidation whereas convulsive does 
impair retention by interfering with the retrieval. 
B.Neurochemical Actions of Pentylenetetrazol 
Introduction 
Pentylenetetrazol (1,5-pentamethylenetetrazole, Metra-
zol) is an analeptic drug which stimulates all levels of the 
neuroaxis. Pentylenetetrazol (PTZ) has been the most exten-
sively studied analeptic, however its mechanism of action is 
poorly understood. Good reviews of the early literature 
(Hildebrandt, 1937; Hahn, 1960) and the chemistry of the 
tetrazole derivatives (Benson, 1947) are available. The pre-
sent review will concern the effect of PTZ on CNS acetylcho-
line, GABA and monoamine metabolism as well as the effect of 
manipulation of brain monoamine levels on PTZ seizure thresh-
old. 
Effect of PTZ on Acetylcholine 
Acetylcholine Levels 
Giarman and Pepeu (1962) sacrificed rats 12 minutes 
after a convulsant (75 mg/kg) dose of PTZ and reported a sig-
nificant (23%) reduction in whole brain acetylcholine. Beani 
et al. (1969) sacrificed guinea pigs 30 sec., 3 min. and 6 
min. after convulsions produced by PTZ (80 mg/kg) and mea-
sured total brain acetylcholine. The animals sacrificed 6 
minutes post PTZ were almost dead at sacrifice with clear 
signs of post-seizure neurodepression. Determination of 
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acetylcholine content in brains of guinea pigs sacrificed at 
30 seconds or 3 minutes post-PTZ showed that the total amount 
of acetylcholine was significantly below control values. The 
reduction in brain acetylcholine produced by PTZ concerned 
only bound ~cetylcholine not free acetylcholine. 
In contrast to the reports of Giarman and Pepeu (1962) 
and Beani· et al. (_1969), Nistri and Pepeu (1974) reported that 
a subconvulsant (80 mg/kg) or a convulsant (160 mg/kg) dose of 
PTZ produced a statistically significant elevation of acetyl-
choline content in the frog spinal cord after 30 and 15 min-
utes, respectively. Bowever, no changes in spinal cord acetyl-
choline levels were noted if the convulsions, interrupted by 
periods oj depression, persisted for 90 minutes. Total frog 
brain acetylcholine content was not altered 15 minutes follow-
ing the administration of the convulsant (160 mg/kg) dose of 
PTZ. 
The discrepant findings on th_e effect of PTZ on acetyl-
choline levels may be due to a different effect of PTZ on the 
manunalian and amphibian central nervous system. 
Acetylcholine Release 
Mitchell (_1963) reported that intravenous administra-
tion of PTZ (~50 mg/kg) increased acetylcholine output from 
the left and right parietal cortex of sheep. In immobilized, 
anesthetized cats Beleslin et al. (1965) found that intraven-
ous infusion of PTZ (20-80 mg/kg) produced a dose-dependent 
increase in the output of acetylcholine into the cerebral 
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ventricles. Acetylcholine output also increased (2-7 fold) 
from the cerebral cortex. Intraperitoneal injection of PTZ 
(150 aRd 300 mg/kg) produced a 2.9 and 7.5 fold increase in 
the release of acetylcholine from the cerebral cortex of an-
esthetized rats (Hemsworth and Neal, 1968). The increased 
release of acetylcholine was nearly maximal during the first 
30 minute period of collection after injection and did not 
appreciably decrease over a period of 3 hours. The increase 
in release of acetylcholine was associated with increased 
electrical activity of the cerebral cortex. 
Gardner and Webster (1973) found that intraperitoneal or 
intravenous administration of PTZ produced a dose-dependent 
++ increase in Ca dependent acetylcholine efflux from the 
cerebral cortex of anesthetized rats which was proportional 
to EEG activation and convulsive activity. A single intra-
peritoneal injection (250 mg/kg) produced a 12-fold increase 
in acetylcholine efflux together with convulsive EEG activa-
tion. Trimethadione reduced the PTZ-induced convulsive ac-
tivity, EEG activation and acetylcholine release. Phenobar-
bital, however, reduced the PTZ-induced EEG and convulsive 
activity but left the acetylcholine release relatively unaf-
fected. Therefore the effect of PTZ on acetylcholine efflux 
may not be related to its convulsant effect. 
Assuming that increased release of acetylcholine from 
brain leads to a reduction in its acetylcholine content the 
studies demonstrating PTZ-induced acetylcholine release are 
in agreement with the reports of Giarman and Pepeu (1962) 
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and Beani et al. (1969) demonstrating a PTZ-induced reduction 
in brain acetylcholine. 
Acetylcholinesterase 
Mahon and Brink (1970) reported that PTZ produced a 
concentration-dependent (Ki= 4.7 x 10- 3 M) competitive inhi-
bition of acetylcholinesterase in crude homogenates of rat 
brain. These authors point out, however, that kinetic con-
stants calculated from their data indicate that the quantity 
of PTZ necessary to cause 50 percent inhibition of acetylcho-
linesterase in vitro is much higher than that amount likely 
to be present in the brain after administration of a convul-
sant dose of the drug. Furthermore inhibition of acetylcho-
linesterase by PTZ would elevate acetylcholine which is con-
tradictory to existing data (Giarman and Pepeu, 1962; Beani 
et al., 1969). 
Nistri et al. (1974) administered PTZ (160 mg/kg) sub-
cutaneously to frogs. Twenty minutes after PTZ administration, 
when convulsive symptoms were present, the animals were 
killed and spinal cord acetylcholinesterase activity was mea-
sured. No significant difference was found between controls 
and animals treated with PTZ. Nistri et al. (1974) suggested 
that the difference between the effect of PTZ on acetylchol-
inesterase in mammalian brain homogenates and amphibian spi-
nal cord in vivo could reflect a higher resistance of the 
amphibian enzyme to PTZ. 
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Choline Uptake 
When rats were sacrificed immediately after the onset 
of the . flexor stage of the convulsion, Simon et al. (1976) 
reported that the intravenous administration of PTZ (75 mg/ 
kg) produced a 45% increase in sodium-dependent high affin-
ity choline uptake inrat hippocampal synaptosomes. This in-
crease was not found, however, when cholinergic afferents 
to the hippocampus were interrupted by septal lesion prior 
to PTZ administration. Injection of a lower, non-convulsant 
(10 mg/kg) dose of PTZ did not result in a change in choline 
uptake. 
Addition of PTZ (10- 4M) to hippocampal synaptosomal pre-
paration from saline treated animals did not alter high af-
finity choline uptake (Simon et al., 1976). Because in 
vitro addition had no effect, Simon et al. (1976) suggested 
that the effect of PTZ is not a direct one synaptosomes but 
may be due to an increase in impulse flow. 
PTZ increased only the Vmax and not the Km of high af-
finity choline uptake (Simon et al., 1976). PTZ is not al-
ter the conversion of [ 3H]-choline to [3H]-acetylcholine 
suggesting that the alteration in uptake is not a secondary 
effect consequent to a change in choline acetyltransferase 
(Simon et al., 1976). 
Jenden et al. (_1976) and Klemm and Kuhar (1979) also re-
ported that convulsant doses of PTZ activated high affinity 
choline uptake in hippocampal synaptosomes. Choline uptake 
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rapidly returned toward normal in post-mortem tissue indicat-
ing the importance of measuring this process immediately af-
ter sacrificing (Klemm and Kuhar, 1979). 
In summary, results of experiments investigating the ef-
fect of PTZ on acetylcholine function suggest that PTZ acti-
vates cholinergic neurons. Such an activation results in 
acetylcholine release, choline uptake and decreased brain 
acetylcholine levels. 
EFFECT OF PTZ ON GABA 
GABA Levels 
Kamrin and Kamrin (1961) sacrificed mice during the 
tonic extension component of a PTZ-induced seizure and re-
ported no difference in the concentration of brain GABA from 
control treated mice. There was also no difference between 
the cerebral concentration of glutamic acid, glycine, taurine 
or aspartic acid in PTZ or control treated mice (Kamrin and 
Kamrin, 1961). Tews et al. (1963) failed to detect any change 
in brain GABA concentration of dogs following tonic-clonic 
seizures produced by intravenous administration of PTZ (40 
mg/kg). Similarly, Sytinskii and Priyatkina (1966) found no 
alteration of GABA concentration in rat brain following convul-
sions produced by PTZ (100 mg/kg). Wood and Peesker (1975) 
determined mouse brain GABA concentration at the onset of 
seizures induced by PTZ and found no difference between PTZ 
treated and saline-treated mice. 
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Nahorski et al. (1970) examined rat brain GABA levels at 
various times after intraperitoneal administration of a con-
vulsant dose (70 mg/kg) of PTZ and found no change in the 
levels of this amino acid until tonic extension when a sig-
nificant rise was observed. A similar increase in GABA lev-
els was also observed when the rats were sacrificed after 
the convulsion. These autho~s point out that the increase in 
GABA levels may be due to anoxic conditions which existed at 
the time of sacrifice. 
In contrast to the above reports indicating either no 
change or an increase in cerebral GABA during convulsions in-
duced by PTZ, Maynert and Kaji (1962) reported that mice given 
PTZ (85 mg/kg) and sacrificed during the first tonic seizure 
showed a small but significant decrease in brain GABA concen-
tration. Wood et al. (1966) reported a slight but not sta-
tistically significant reduction brain GABA levels when rats 
were sacrificed 5 minutes after a convulsant dose (60 mg/kg) 
of PTZ. 
GABA Release 
-4 -6 Johnston and Mitchell (1971) found that PTZ (10 -10 M) 
inhibited the resting but not the electrically evoked release 
of [3HJ-GABA from rat brain cerebral cortical slices. By ex-
amining the release of [ 3HJ-GABA from feline cortical slabs, 
Reiffenstein (1979) tested the hypothesis that seizure sus-
ceptibility of the chronically denervated cortex was due to 
interruption of recurrent inhibitory pathways. PTZ-induced 
seizures evoked a small increase in [ 3H]-GABA efflux from 
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both the epileptic and the normal cortex. Because interrup~ 
tion of recurrent inhibitiory pa~hways would result in de-
creased resting and seizure-evoked release of [ 3H]-GABA the 
above hypothesis was not supported. 
GAD/GABA-T 
Wood et al. (1966) reported that PTZ (60 mg/kg) did 
not significantly reduce GAD activity in rat brain when rats 
were sacrificed 5 minutes after PTZ-induced seizures. Simi-
larly, Syntinskii and Priyatkina (1966) found no alteration 
in GAD activity produced by PTZ either in vivo or in vitro. 
Tapia et al. (1969) also reported a lack of effect of PTZ on 
GAD activity. 
Sytinskii and Priyatkina (1966) reported that GABA-T ac-
tivity in rat brain was not changed either by in vivo admin-
istration of a convulsant dose of PTZ or by the in vitro ad-
dition of PTZ. However, Wood et al. (1966) reported that PTZ 
(60 mg/kg) produced a significant increase in GABA-T activity. 
The increase in GABA-T activity was not correlated, however, 
with decreased GABA levels . 
Uptake 
-4 Johnston and Mitchell (1971) reported that PTZ (10 -
10- 6 M) did not alter [ 3H]-GABA uptake into rat cerebral cor-
tical slices. 
Effectiveness of GABA and GABA-Mimetic Drugs Against PTZ 
Hawkins and Sarett (1957) found that orally adrninis-
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tered GABA protected mice from PTZ-induced convulsions. Wood 
et al. (1966) reported that GABA but not glycine in a dose of 
120 rnrn9les/kg) administered intraperitoneally produced a 
slight protection against PTZ-induced convulsions in the rat. 
However, several investigators (Purpura et al., 1958 a,b; 
Gulati and Stanton, 1960; were unable to demonstrate an anti-
convulsant action of GABA following systemic administration. 
Kobrin and Seifter (1966) reported that intravenous ad-
ministration of GABA (25-1000 mg/kg) to 1 day old chicks in 
which the blood-brain barrier was not complete produced a 
dose-dependent protection against convulsions induced by PTZ 
(35 mg/kg) also administered intravenously. Several other 
w-amino acids including glycine and B-alanine were ineffec-
tive. When GABA was administered to older chicks in which 
the blood-brain barrier was developed it was ineffective in 
protecting against PTZ-induced convulsions. Schlesinger 
et al. (1969) found that intracranial injection of GABA pro-
tected mice against PTZ-induced seizures. 
Elevations of brain GABA levels with the GABA-T inhibi-
tors, amino-oxyacetic acid (Roa et al., 1969; Kuriyama et al., 
1966; Wood and Peesker, 1975), hydroxylamine (Roberts et al., 
1960) or valproic acid (Simler et al., 1973) affords protec-
tion against PTZ-induced convulsions. However, Maynert et 
al. (1962) showed that a three-fold elevation of brain GABA 
produced by hydrazine did not protect mice against PTZ con-
vulsions. Similarly, Schecter et al. (1977) reported that a 
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six-fold elevation of brain GABA produced by gamma-acetylenic 
GABA did not protect mice against seizures induced by PTZ. 
Frey et al. (1979) examined the role of GABA mechanisms 
in PTZ convulsions by investigating the effect of inhibition 
of high affinity GABA uptake on PTZ-induced convulsions. The 
ability of inhibitors of high affinity GABA uptake blockers 
to increase the PTZ seizure threshold correlated well with 
the ability of these drugs to inhibit GABA uptake in vitro. 
(-)-Nipecotic acid had the most pronounced effect. This ef-
fect of the GABA uptake blockers was not correlated with al-
teration in brain GABA levels or changes in GAD or GABA-T 
activities. 
The GABA receptor agonist muscimol also elevated the PTZ 
convulsant threshold and this was accompanied by decreased 
brain GABA concentration and GAD activity (Frey et al., 1979). 
Effectiveness of PTZ Against GABA 
Presynaptic inhibition is thought to be mediated by 
GABA (Barker and Nicoll, 1972; Curtis and Johnston, 1974; 
Davidoff, 1972; Davidson and Southwick, 1971) and several in-
vestigations have been directed towards examining the effect 
of PTZ on GABA mediated presynaptic inhibition. Boyd et al. 
(1966) reported that PTZ blocked GABA mediated presynaptic 
inhibition in the cuneate nucleus. Similarly, Banna and 
Hazbun (1969) and Hill et al. (1974) found that PTZ reduced 
GABA-mediated presynaptic inhibition. Nicoll and Padjen 
(1976) found that PTZ in concentration of >l0- 2M antagonized 
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the action of GABA at primary afferents of the isolated frog 
spinal cord. 
While it appears clear that PTZ blocks GABA-mediated pre-
synaptic inhibition, evidence on the effect of PTZ on GABA me-
diated post-synaptic inhibition is contradictory. Krnjevic 
et al. (~9661 reported that PTZ did not block cortical inhibi-
tion mediated by GABA and Hill et al. (1973a) reported that 
slow intravenous infusion of PTZ to cats produced seizure ac-
tivity without antagonizing the effect of iontophonetic ap-
plication to the cortex. 
Microiontophoretic application of PTZ (lM) to single fe-
line cortical neurons failed to antagonize the inhibitory ef-
fects. of GABA (_Hill et~ al., 1973b) . However, the authors cau-
tioned that a sufficient concentration of PTZ to produce GABA 
antagonism may not h.ave been achieved in the area of the 
neuron when PTZ was applied iontophoretically. 
In contrast to th.e above studies showing lack of an ef-
feet of PTZ on GABA-mediated post-synaptic inhibition, Mac-
Donald and Barker (1977) reported that iontophoretically ap-
plied pTZ (_0.3Ml competitively inhibited GABA-mediated post-
synaptic responses in cultured mammalian spinal cord neurons. 
Similarly, Scholfield (1979) found that PTZ antagonized the 
post~·synapt.tc action of GABA on 9uinea pig olfactory cortical 
neurons. 
In summary, while PTZ does not alter brain GABA concen-
tration, GAD or GABA-T activity it has been demonstrated that 
GABA and some GABA-mimetic drugs antagonize the convulsant 
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action of PTZ. Furthermore, PTZ has been reported to block 
both pre- and post-synaptic inhibition mediated by GABA. 
EFFECT OF PTZ ON MONOAMINE METABOLISM 
Bonnycastle et al. (1957) reported that a convulsant dose 
(75 mg/kg) of PTZ failed to alter rat brain serotonin levels. 
However, Bertaccini (1959) found that rat brain serotonin con-
centration was elevated 20-30% when the animals were sacri-
ficed 15-60 minutes after convulsions. Garattini et al. (1960) 
also reported that PTZ increased the brain serotonin content 
and that this effect was independent of convulsions. 
Kato et al. (1967) looked at the effect of acute and 11 
day treatment of PTZ (50 mg/kg) in rats. When the animals 
were sacrificed 5 minutes after an acute injection there was 
an increase in 5-HT levels. At 2 hours 5-HT levels had re-
turned to normal but were elevated 3-fold at 24 hours. Sac-
rificing the rats 5 minutes or 24 hours after 11 day PTZ 
treatment resulted in marked elevation of 5-HT levels at all 
times. 
Diaz (1970) injected a subconvulsant (30 mg/kg) dose of 
PTZ to rats and reported a 42% increase in brain serotonin 
level and a 34% decrease in 5-HIAA level when the animals 
were sacrificed 30 minutes after injection. Administration 
of a convulsive (50 mg/kg) dose of PTZ produced an 18% in-
crease in 5-HT level but no change in 5-HIAA level. PTZ 
(.30 mg/kg) produced a significant (48%) decrease in the rate 
of 5-HT synthesis, however, 50 mg/kg had no significant 
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effect. The rate of depletion of 5-HT following reserpine was 
significantly decreased by PTZ (30 mg/kg) but not the convul-
sant d9se. These data show that PTZ alters brain 5-HT metab-
olism and that this effect is not dependent on seizures. 
McMillen and Isaac (1974) reported the effect of PTZ (10-
50 mg/kg) on serotonin and dopamine metabolism in the cat. 
Intraperitoneal administration of PTZ (10 mg/kg) produced no 
change in the CSF concentration of either 5-HIAA or HVA. A 
larger, also non-convulsant dose (20 mg/kg) increased the 5-
HIAA concentration by 103% four hours after injection and 
5-HIAA levels remained elevated for 24 hours. HVA levels were 
not significantly altered by this dose of PTZ. When the cats 
were administered 30 mg/kg they exhibited a "pseudoconvulsion" 
which was characterized by clonus and vocalization. This 
dose of PTZ increased 5-HIAA levels 44% after 4 hours and the 
level remained elevated for 24 hours. HVA levels were found 
to be increased 27% after 2 hours but this did not remain ele-
vated for 24 hours as did 5-HIAA levels. Clonic convulsions 
occurred following the administration of a convulsant dose 
(50 mg/kg) of PTZ. This dose produced elevation of 5-HIAA 
and HVA which lasted 24 hours. These data show that non-con-
vulsant doses of PTZ increased metabolic activity in the 5-HT 
system for up to 24 hours while not affecting dopamine sys-
tems and that convulsions induced by PTZ cause a non-specific 
increase in the metabolism of dopamine systems as well. 
McMillen and Isaac (1978) later reported that the in-
crease in 5-HIAA levels reported to occur after administration 
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of 20 mg/kg PTZ (McMillen and Isaac, 1974) was probably secon-
dary to a reduction in body temperature produced by the drug 
since ~aintaining body temperature prevented the increase in 
5-HIAA produced by this dose of PTZ. Injection of a convul-
sant dose (40 mg/kg) of PTZ increased 5-HIAA levels and this 
effect was not prevented by controlling body temperature. 
This indicates that convulsant doses of PTZ can increase 5-HT 
metabolism but after non-convulsant doses the increase in 
5-HT metabolism is secondary to the hypothermic effect of PTZ. 
Determination of PTZ concentration in plasma and CSF 
showed that PTZ was not present to exert an effect at 24 hours, 
therefore the increased levels of 5-HIAA and HVA at this time 
was not due to the presence of PTZ (McMillen and Isaac, 1978). 
PTZ (20 mg/kg) did not alter plasma tryptophan levels 
and a 40 mg/kg dose decreased total plasma tryptophan. !This 
change is opposite to the change observed in CSF 5-HIAA 
(McMillen and Isaac, 1978). These data suggest that the 24 
hour increase in CSF 5-HIAA levels does not result from an in-
crease in plasma tryptophan levels and may be a direct effect 
of PTZ on 5-HT neurons. 
Pretreatment of cats with trimethadione (200 mg/kg) 
blocked the convulsions but not the EEG excitation produced 
by PTZ (40 mg/kg). This dose of PGZ elevated 5-HIAA levels 
whether or not the animals were pretreated with trimethadione 
suggesting that PTZ can increase 5-HT metabolism without caus-
ing convulsions (McMillen and Isaac, 1978). 
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The results of Diaz (1970) and McMillen and Isaac (1974, 
1978), with respect to the effect of PTZ on 5-HIAA levels, 
are opposite. This discrepancy can best be explained by dif-
ferences in the period of measurement of 5-HT metabolism. In 
addition to its effect on 5-HT and dopamine metabolism, Kato 
et al. (1967) reported that acute administration of PTZ (50 
mg/kg) resulted in elevated levels of brain histamine 24 hours 
after injection. Epinephrine levels were decreased at 5 min-
utes and 2 hours after PTZ, not changed after 1 hour and ele-
vated after 24 hours. Norepinephrine levels were increased 
at 5 minutes, 1 hour and 2 hours but had returned to normal 
at 29 hours. Eleven day treatment with PTZ (50 mg/kg) pro-
duced marked elevation in brain histamine but not epinephrine 
or norepinephrine (Kato et al., 1967). 
In summary, the above studies show that PTZ affects mono-
amine metabolism at both non-convulsant and convulsant doses. 
Furthermore, these effects can last long after the immediate 
action of PTZ has stopped. 
Effect of Monoamine Manipulation on PTZ Seizure Threshold 
Bonnycastle et al. (1957) reported that elevation of rat 
brain 5-HT levels by administration of either iproniazid or 
5-HTP failed to protect rats against the convulsant or lethal 
effect of PTZ (75 mg/kg). However, Frey and Kilian (1973) 
found that 5-HTP increased the PTZ seizure threshold of both 
mice and rats. Rudzik and Johnson (1970) reported that ad-
ministration of tranylcypromine, 5-HTP or 3,4-dihydroxyphenyl-
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alanine (DOPA) did not alter the PTZ seizure threshold. How-
ever, when 5-HTP was combined with tranylcypromine a signifi-
cant elevation in the PTZ convulsive threshold occurred. In 
contrast the combination of tranylcypromine and DOPA did not 
increase the threshold for PTZ seizures. 
The survival time of mice infused intravenously with PTZ 
is shortened by reserpine (Chen et al., 1954; Lessin and 
Parkes, 1959; Pfeifer and Galambos, 1967) or tetrabenazine 
(Lessin and Parkes, 1959) pretreatment. Administration of 
the MAO inhibitor, iproniazid, prevented the reduction in sur-
vival time produced by reserpine (Chen and Bohner, 1961; 
Lessin and Parkes, 1959; Pfeiffer and Galambos, 1967) or tet-
rabenazine (Lessin and Parkes, 1959). 5-HTP lengthened the 
survival time of mice pretreated with iproniazid but had no 
effect alone. In contrast, DOPA did not alter the survival 
time of mice pretreated with iproniazid (Lessin and Parkes, 
1959). LSD but not 2-bromo-LSD antagonized the effect of 
reserpine on PTZ survival time. LSD did not alter the sur-
vival time of control mice (Lessin and Parkes, 1959) . These 
data suggest a relationship between sensitivity to PTZ and 
brain 5-HT levels. Chen and Bohner (1961) reported that in 
addition to 5-HTP, 5-HT, DOPA and dopamine reversed the low-
ering effect of reserpine on PTZ seizure threshold in ipro-
niazid treated mice. 
Jones and Roberts (1968) found that intracerebroventricu-
lar injection of noradrenaline antagonized reserpine-induced 
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facilitation of PTZ seizures but had no effect alone. Where-
as small amounts of intraventricularly administered dopamine 
lowere~ the threshold for PTZ convulsions and were without 
effect on the reserpine facilitative effect, higher doses 
showed anti-convulsant action and antagonized the facilitative 
effect of reserpine. Schlesinger et al. (1969) reported that 
the combined intracranial injection of norepinephrine plus 
5-HT protected mice against PTZ-induced seizures. 
Pfeiffer and Galambos (1967) suggested that norepinephrine 
has a more important role in the change of susceptibility to 
PTZ seizures than 5-HT or dopamine. These investigators found 
that prenylamine decreased the PTZ convulsive threshold with-
out altering 5-HT levels. Also guanethidine decreased only 
brain norepinephrine levels without altering dopamine or 5-HT 
and lowered the threshold for PTZ-induced convulsions. 
Alexander and Kopeloff (1970) found that pretreatment of 
rats with p-chlorophenylalanine (PCPA) to deplete brain sero-
tonin lowered the threshold for PTZ-induced seizures. Frey 
and Kilian (197 3) pretreated mice with PCPA or cyprohepta-
dine and found no change in the threshold for PTZ-induced 
clonic seizures. However, PCPA lowered the threshold in rats 
confirming the data of Alexan'.der and Kopeloff (1970). 
Rudzik and Johnson (1970) reported the PTZ convulsive 
threshold in mice was lowered only by drugs which decreased 
whole brain 5-HT and was not altered by catecholamine deplet-
ing drugs. Reserpine and P-CPA were found to lower the sei-
zure threshold but U-14,624 and alpha-methyl-para-tyrosine 
produced no chage. 
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In contrast to these data, Frey and Kilian (1973) re-
ported that alpha-methyl-para-tyrosine, disulfarim, FLA-63 
and pr?pranolol but not haloperidol or phentolamine lowered 
the threshold for PTZ-induced clonic seizures. L-dopa ele-
vated this threshold in mice but had no significant effect in 
rats. Because dopamine B-hydroxylase inhibitors were as ef-
fective as alpha-methyl-para-tyrosine and because of the lack 
of effectiveness of haloperidol these data suggest a more im-
portant role for norepinephrine than dopamine. 
The threshold for PTZ-induced tonic extension was de-
pressed by FLA-63, PCPA, cyproheptadine and propranolol but 
not alpha-methyl-p~ra-tyrosine or disulfarim (Frey and Kilian, 
1973). 
Corcoran et al. (1973, 1974) found that selective destruc-
tion of catecholamine but not 5-HT neurons by intraventricular 
injection of 6-0HDA to rats pretreated with an MAO inhibitor 
increased the duration and intensity of convulsions induced by 
PTZ (70 mg/kg). The severity of seizures in rats with deple-
tion of both norepinephrine and dopamine was not different 
from rats with preferential depletion of norepinephrine, sug-
gesting that norepinephrine and not dopamine is important for 
the 6-0HDA induced exacerbation of PTZ convulsions. 
A number of investigations have looked at the effect of 
amphetamines on PTZ seizure threshold. Kobinger (1958) found 
that methamphetamine raised the PTZ seizure threshold when 
administered 15 minutes before PTZ. Methamphetamine also an-
tagonized the decreased PTZ seizure threshold produced by 
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reserpine. Turner and Spencer (1968) however, reported that 
d-amphetamine had a pro-convulsant effect on PTZ convulsions 
in mice when administered 30-90 minutes before PTZ but had an 
anticonvulsant effect when administered 6 hours before PTZ. 
BLockade of dopamine but not norepinephrine or 5-HT synthesis 
antagonized the pro-convulsant action of d-amphetamine 
(Spencer and Turner, 1969) indicating the importance of dop-
amine for this action. 
Rudzik and Johnson (1970) reported that neither d-amphet-
amine or metharnphetarnine significantly altered the PTZ con-
vulsive threshold but administration of the chloroderivatives 
which have a unique effect on 5-HT disposition (Fuller et al., 
1965) produced a significant increase of the PTZ seizure 
threshold. Gerald and Riffee (1973) found that acute admin-
istration of d- or 1-amphetamine increased susceptibility to 
PTZ-induced convulsions. d-Arnphetamine was about twice as 
potent as the 1-isomer. Whereas 1-arnphetamine increased tonic 
seizure susceptibility, d-amphetarnine decreased susceptibil-
ity to this seizure. Tolerance developed to these effects 
of amphetamine after seven consecutive daily injections 
(Gerald and Riffee (1973)). 
Finally, Bhattacharya and Sanyal (1978) reported that 
prostaglandin E, (PGE1 ) induced inhibition of PTZ-induced 
seizures in rats was antagonized by drugs which reduce brain 
5-HT activity but not by drugs which decrease catecholamine 
activity. Pretreatment with reserpine, P-CPA, methysergide 
or 5,6-DHT significantly antagonized PGE1 induced inhibition 
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of convulsions produced by PTZ (60 mg/kg). Alpha-methyl-para-
tyrosine, diethyldithiocarbamate, phenoxybenzamine, proprano-
lol or . haloperidol pretreatment did not significantly alter 
the effect of PGE1 . These data suggest that this effect of 
PGE1 is not a direct one but is mediated through serotoniner-
gic mechanisms. 
In summary, manipulation of CNS monoamines has provided 
information regarding the involvement of these neurotrans-
mitters in the convulsant action of PTZ. The majority of 
evidence suggests that reduction of 5-HT or noradrenergic 
activity increases the susceptibility to PTZ seizures. 
CONCLUSION 
Studies to elucidate the action of PTZ on neurotrans-
mitter metabolism have demonstrated that this drug affects 
the metabolism of acetylcholine, GABA and monoamines. A 
uniform neurochemical mechanism for the pharmacological ac-
tions of PTZ, however, is not apparent. 
In addition to its effect on neurotransmitter function, 
PTZ has also been reported to have a direct effect on mem-
brane excitability (Gross and Woodbury, 1972; Klee et al., 
1973; David et al., 1974; Suguya and Onozuka, 1978) which 
may contribute to its action. 
32 
METHODS 
Subjects 
A total of 44 male hooded rats of the Long-Evans strain 
(Charles River Breeding Laboratories, Wilmington, MA) weigh-
ing between 250 and 300 g at the beginning of the investiga-
tion were used as subjects. Animals were housed in single 
cages in a large colony room thermostatically maintained at 
21 + 1°C. Room lights were turned off from 8:00 p.m. to 
8:00 a.m. Water was continuously available in the home cages 
but food was restricted to 20 g a day made available approx-
imately 4 hours following each operant session. 
Apparatus 
The behavioral apparatus consisted of conventional Skinner 
boxes 24 x 30 cm and 26 cm high enclosed in lightproof, sound-
attenuated, and fan-ventilated chambers. Each Skinner box 
contained two response levers which were 2~5 cm wide and which 
extended 2.0 cm into the operant boxes. One lever was on ei-
ther side of a food cup which was installed in the center of 
the short wall equidistant from each lever. Scheduling of 
behavioral contingencies and recording of data was made by a 
combination of eiectromechanical (Lehigh Valley Electronics, 
Lehigh Valley, PA) and solid-state (Coulbourn Instruments, 
Lehigh Valley, PA) programming equipment. 
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PTZ-Saline Discrimination Training 
All of the rats were first magazine trained and shaped 
to lever press for food reinforcement. When the rats began 
to lever press at a rate of one response per minute they were 
shaped to learn a progressively increasing fixed ratio (FR) 
schedule of reinforcement until they consistently responded 
on an FR 10 schedule (10 lever presses for each 45 mg Noyes 
food pellet) . In the beginning only responses with one of 
the levers was reinforced while responding with the other 
lever was not reinforced. When the rats began to respond 
with only one lever at a rate of 20 responses per minute the 
lever with which responses were reinforced was changed to 
the alternate lever. When the rats began to respond with 
this lever at a rate of 20 responses per minute, the lever 
with which responses were reinforced was again changed. Af-
ter 4-5 such alternations without any injection, a PTZ-saline 
injection schedule was introduced. In this phase of train-
ing, daily 15 minute sessions were preceded by injection of 
either PTZ (20 mg/kg) or saline (1 ml/kg). Each session be-
gan with one food pellet in the food cup so as to orient the 
rats to the manipulanda. The animals were trained to respond 
with one of the levers 15 minutes following a PTZ injection 
and the other lever 15 minutes following a saline injection 
(Figure 1). Every tenth response (FR 10) with the appropri-
ate lever was reinforced by delivery of a 45 mg Noyes food 
pellet. Responses with the incorrect lever (i.e., saline 
Figure 1. Diagrammatic representation of the PTZ-
sa:iLi:ne discrimination . procedure. On an FR 10 schedule 
of food reinforcement, hungry rats were trained to re-
spond with a lever on one side of a food cup 15 min 
following a 20 mg/kg PTZ injection and to respond with 
the lever on the alternate side 15 min following a 
1 ml/kg saline injection. 
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lever following PTZ injection or PTZ lever following saline 
injection) were recorded but were not reinforced by delivery 
of food. 
To guard against a possible effect of lever or position 
preference the lever with which responses were reinforced 
following a PTZ injection was randomly assigned to be the 
lever on the right side of the food cup for half of the rats 
and the lever on the left side of the food cup for the re-
maining rats. For each rat, the position (i.e., right or 
left) of the PTZ lever remained constant on each subsequent 
session . To avoid the possibility that olfactory cues asso-
ciated with the correct lever for rats previously tested in 
the Skinner boxes could serve as a cue for lever selection 
(Weissman, 1976), the sequence of PTZ-saline injections was 
varied separately for each group of rats trained successive-
ly on the same day. 
Initially, the sequence of PTZ-saline injections alter-
nated. This training continued until five such alternations 
were achieved and responding was stabilized with the appro-
priate lever. Following this the rats entered the final 
phase of training where the PTZ-saline sessions were carried 
out seven days a week according to an irregularly alternat-
ing sequence of PTZ-saline injections. In this and all sub-
sequent phases of the experiment, the session length was 
fixed at 10 minutes. The rats were trained to a criterion of 
emitting four or less responses with the incorrect lever 
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prior to the first reinforcement (10 responses with the cor-
rect lever) on nine out of ten consecutive sessions. 
Fbr each session data were recorded automatically to in-
clude the number of responses emitted with the incorrect le-
ver prior to th_e first reinforcement as well as the total 
number of responses emitted with. the correct and incorrect 
lever during the entire 10 minute session. 
Discrimination Testing_ 
Wh.en the rats reached the c,riterion described above they 
were continuously and repeatedly used for generalization and 
anta9onism tes-ting-. These tests consisted of ten-minute ses-
sions separ~ted by at least five practice sessions in which 
saline and PTZ wer-e correctly discriminated. For half of 
the rats, the sessions were ·preceded by a practice session 
in which saline was injected whereas for the remaining rats 
test sessions were preceded by a practice session in which 
PTZ was injected. If the rats• pe~formance on these prac-
tice sess·ions seemed to deteriorate with respect to the num-
ber of responses on the incorrect lever prior to the first 
reinforcement, further training sessions were given before 
testing was reinstated. For generalization and antagonism 
testing, doses of each drug were administered in an irregu-
lar order. 
A. Generalization Testi·ng ~ Following injection of the 
test drug (for pretreatment time see Table 3) each rat was 
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placed in its assigned Skinner box and allowed to respond with 
the levers until ten nonreinforced responses were completed 
with one of the levers. The lever with which ten responses 
were completed first was considered the selected lever and 
was subsequently fixed to be reinforced (FR 10) for the re-
mainder of the session. Responses emitted with the other le-
ver were recorded but not reinforced. 
B. Antagonism Testing - Animals were injected with the 
appropriate dose of the test drug or saline. Following this 
pretreatment (for pretreatment time see Table 5), the rats 
were injected with pentylenetetrazol (20 mg/kg). Fifteen 
minutes after the pentylenetetrazol injection the animals 
were placed in their assigned Skinner boxes and tested for 
lever selection as described above. 
C. Antagonism Testing with Diazepam and Chlordiapep-
oxide After Their Chronic Administration - The rats that were 
tested acutely with diazepam (2.5 or 10 mg/kg) for antagonism 
of the PTZ discriminative stimulus were treated with diazepam 
(10 mg/kg) for ten consecutive days. Similarly, the animals 
tested acutely with chlordiazepoxide (2.5 or 10 mg/kg) were 
treated with chlordiazepoxide (10 mg/kg) for ten consecutive 
days. Other rats that were tested acutely with solvent were 
treated with solvent for ten consecutive days. Results of 
previous studies (Cook and Sepinwall, 1975; Goldberg et al., 
1967; Margules and Stein, 1968; Stein et al., 1975) suggest 
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this treatment regimen to be more than sufficient to develop 
tolerance to the sedative effects of benzodiazepines. No 
discri~ination training or test trials were administered dur-
ing this period. On the eleventh, twelfth and thirteenth 
days, animals were injected with the appropriate dose of ei-
ther diazepam, chlordiazepoxide or solvent and tested for 
antagonism of the PTZ discriminative stimulus as described 
above for the acute study. To maintain tolerance for these 
days the rats were injected daily with the appropriate drug 
four hours after each operant session so that the chronic 
dosing schedule was maintained. 
D. Test for Diazepam Antagonism O"f the Discriminative 
Stimuli Produced by Cocaine, Yohimb'ine ·and R05-3663 in Rats 
Trained to Discriminate Between PTZ and Saline - On these 
tests rats were treated with diazepam (5 mg/kg) 30 min. be-
fore injection of yohimbine (2.5 mg/kg) or ROS-3663 (5-20 
mg/kg). Thirty min or 1 h after the cocaine injection and 
30 min after yohimbine or ROS-3663 injection the rats were 
tested for lever selection as described previously. 
E. Test for Diazepam and Halbperidc>l Antagohis:m of 
Discriminative Stimulus Produced by Cocaine ih Rats Tra·i ·ned 
to Discriminate Between PTZ and Saline - On these tests rats 
were injected with diazepam (5 mg/kg) or haloperidol (0.16 
or 0.69 mg/kg) 30 or ~O min before injection of cocaine 
(20 mg/kg), respectively. Fifteen min after the cocaine in-
jection the rats were tested for lever selection as described 
previously. 
Drugs 
The drugs used in this study (listed in alphabetical or-
der) were aceperone (Janssen Pharmaceutica N.V., Beerse, 
Belgium); amitriptyline hydrochloride (Merck and Co. Inc., 
Rahway, NJ); d-amphetamine sulfate (Smith, Kline and French 
Laboratories, Philadelphia, PA); apomorphine hydrochloride 
(Eli Lilly and Co., Indianapolis, IN); atropine sulfate (Merck 
and Co. Inc. Inc., Rahway, NJ); bemegride (Aldrich Chemical 
Co. Inc., Milwaukee, WI); bicuculline methiodide (Pierce Lab-
oratories, Rockford, IL); caffeine citrate (The New York 
Quinine and Chemical Works, Inc., New York, NY); carbachol 
(Aldrich Chemical Co. Inc., Milwaukee, WI); chlordiazepoxide 
hydrochloride (Hoffman LaRoche Inc., Nutley, NJ); chlorproma-
zine (Smith, Kline and French Laboratories, Philadelphia, PA); 
clobazam (Hoechst-Roussel Pharmaceuticals Inc., Somerville, 
NJ); clonazepam (Hoffman LaRoche, Inc., Nutley, NJ); clonidine 
hydrochloride (Boehringer Ingelheim Ltd., Ridgefield, CT); 
cocaine hydrochloride (Merck and Co. Inc., Rahway, NJ); dia-
zepam (Hoffman LaRoche Inc., Nutley, NJ); diphenylhydantoin 
(Kand K Laboratories, Plainview, NY); ethanol (U.S. Industri-
al Chemical Co., New York, NY); ethosuximide (Parke, Davis 
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and Co., Detroit, MI); etomidate sulfate (Janssen Pharmaceutica 
N.V., Beerse, Belgium); £luoxetine (Eli Lilly and Co., Indian-
apolis, IN); flurazepam dihydrochloride (Hoffman LaRoche Inc., 
Nutley, NJ); gamma-acetylenic GABA (Merrell International Re-
search Center, Strasbourg, France); gamma-hydroxybutyrate 
(Aldrich Chemical Co., Milwaukee, WI); gamma-vinyl GABA (Merrell 
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International Research Center, Strasbourg, France), haloperi-
dol (McNeil Laboratories Inc., Fort Washington, PA); 5-DL-
hydroxytryptophan (Aldrich Chemical Co., Milwaukee, WI); 
meprobamate (Wallace Laboratories, Cranbury, NJ); 3-mercapto-
proprionic acid (Sigma Chemical Co., St. Louis, MO); methyl-
phenidate hydrochloride (Ciba-Geigy Corp., Summit, NJ); methy-
sergide maleate (Sandoz Pharmaceuticals, Hanover, NJ); mor-
phine sulfate (Merck and Co. Inc ., Rahway, NJ); naloxone hy-
drochloride (Endo Laboratories, Garden City, NJ); nicotine 
(Aldrich Che:mical Co. Inc., Milwaukee, WI) ; oxotremorine 
(Aldrich Chemical Co., Milwaukee, WI); pentobarbital (American 
Pharmaceutical Co., Bronx, NY); pentylenetetrazol (Sigma Chemi-
cal Co., St. Louis, MO); phenobarbital (American Pharmaceuti-
cal Co., Bronx, NY); physostigmine sulfate (Merck and Co. 
Inc., Rahway, NJ): picrotoxin (Aldrich Chemical Co. Inc., 
Milwaukee, WI); propranolol hydrochloride (Ayerst Laboratories, 
Inc., New York, NY); ROS-3663 (Hoffman LaRoche Inc., Nutley, 
NJ}; scopolamine hydrobromide (Robbins Research Laboratories, 
Richmond, VA}; strychnine sulfate (Mallinckrodt Chemical 
Works, St. Louis, MO); trimethadione (Abbott Laboratories, 
North Chicago, IL); valproic acid (Abbott Laboratories, North 
Chicago, lL); and yohirnbine hydrochloride (Sigma Chemical Co., 
St. Louis, ,MO}. 
Dizepam, clobazam, clonazepam and meprobamate were homo-
genized in 0.9% saline containing 13% propylene glycol and 1% 
Tween 80. Ealoperidol was dissolved in 0.3% tartaric acid. 
Trimethadione was dissolved in 0.9% saline containing 40% 
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propylene glycol and 10.5% ethyl alcohol. All other drugs 
were dissolved in 0.9% saline. 
All drugs were administered intraperitoneally in a volume 
of 1 ml/kg except caffeine citrate, clobazam, diazepam, di-
phenylhydantoin, ethanol, ethosuximide, ganrrna-hydroxybutyrate, 
naloxone hydrochloride, R05-3663, trimethadione and valproic 
acid and yohimbine hydrochloride which were administered in a 
volume of 2-8 ml/kg. Drug doses were calculated in terms of 
the salt. 
Statistical Analyses 
Lever selection data was expressed as a percentage of 
rats selecting the PTZ lever following each drug treatment. 
The Fisher Exact Probability Test was used to determine sta-
tistical significance of results. Drug treatments were con-
sidered to significantly generalize to the PTZ discriminative 
stimulus if the Fisher Exact Probability Test revealed that 
such treatments resulted in a percentage of rats selecting the 
PTZ lever that was not significantly (p >0.05) different from 
the percentage of rats selecting the PTZ lever after injec-
tion of PTZ (20 mg/kg). Drug pretreatments were considered 
to significantly antagonize the PTZ discriminative stimulus 
if the Fisher Exact Probability Test revealed that such treat-
ments resulted in a percentage of rats selecting the PTZ 
lever that was significantly different (p <0.05) from the per-
centage of rats selecting the PTZ lever after saline pre-
treatrnen t. 
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Regression analysis was performed to determine whether 
generalization to or antagonism of the PTZ discriminative 
stimulns by a drug treatment was a dose-related effect. Drug 
treatments were considered to produce a significant dose-
related effect if by regression analysis p < 0. 05. ED 50s and 
95% confidence limits were calculated according to Finney 
( 19 52) . 
To determine whether a drug treatment significantly af-
fected response rate, One Way Analysis of Variance (ANOVA) 
was performed to compare mean test session response rate with 
mean response rate of the PTZ and saline sessions preceding 
the test. A drug treatment was considered to significantly 
affect response rate if One Way ANOVA revealed a statically 
significant (p < 0.05) difference among the treatment means. 
If One Way ANOV revealed a statistically significant differ-
ence among treatment means, a Duncan's Multiple Range Test 
(Duncan, 1955) was performed to determine which particular 
mean differed from another particular mean. Mean response 
rates were considered to significantly differ from each oth-
er by Duncan's vultiple Range Test if p<0.05. 
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RESULTS 
Acquisition of the PTZ-Saline Discrimination 
All of the rats acquired the PTZ-saline discrimination 
to the required criterion. The number of sessions needed to 
reach this criterion ranged from 16 to 49, the mean (~S.E.M.) 
being 30+ 1.1. Acquisition of the PTZ-saline discrimination 
is shown in Figure 2. On the first training session, 43% of 
the rats injected with PTZ selected the PTZ lever and 55% of 
-
the animals injected with saline selected the PTZ lever. On 
the twentieth training session, 73% of the rats injected with 
PTZ selected the PTZ lever and 28% of the rats injected with 
saline selected the PTZ lever. By the thirty-sixth training 
session, 95% of the animals injected with PTZ selected the 
PTZ lever and 10% of the animals injected with saline selec-
ted the PTZ lever. 
The number of responses emitted with the incorrect lever 
prior to correct lever selection during acquisition of the 
PTZ-saline discrimination is shown in Table 1. On the first 
PTZ training session, the rats emitted 31+11.l responses 
with the saline lever before selecting the PTZ lever. On 
the first saline session the rats emitted 34~6.8 responses 
with the PTZ lever before selection of the saline lever. On 
the twentieth training session the rats injected with PTZ 
emitted 13+4.0 responses with the saline lever prior to 
4 4 
Figure 2. Acquisition of PTZ-saline discrimination. Values 
are the percentage of rats selecting the PTZ 
lever or the indicated training session when an 
injection of PTZ or saline was given. Data are 
based on 44 rats. 
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TABLE 1. Responses Emitted with the Incorrect Lever Prior to 
Lever Selection During Acquisition of the Pentylene-
tetrazol (20 mg/kg) - Saline Discrimination 
Training 
Session 
Injection 
Numberl 
1 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
30 
32 
34 
36 
Responses with Saline 
Lever Following PTZ 
(20 mg/kg) Injection 
(Mean+ S.E.)2 
31+11.l 
18+4.7 
22+5.5 
15+3.5 
10+1.9 
8+2.2 
7+1.7 
8+2 . 6 
7+2.1 
13+4.0 
5+1.6 
6+2.7 
11+3.3 
4+1.3 
6+2.3 
3+1.0 
4+1.7 
1+0.6 
Responses with PTZ 
Lever Following 
Saline Injection 
(Mean+ S.E.)3 
34+6.8 
39+9.l 
27+4.7 
21+6.0 
22+5.5 
16+5.l 
14+3.l 
11+3.5 
11+3.6 
8+2.3 
8+3.2 
·9+2. 6 
9+2.0 
7+2.0 
2+0.5 
5+1.6 
5+1.7 
3+1.2 
1PTZ or saline were administered daily in an irregularly al-
ternating sequence. 
2Responses (Mean+S.E.) emitted with the saline lever prior to 
selection of the-PTZ lever (10 responses with PTZ lever) on 
days when PTZ (20 mg/kg) was injected. 
3Responses (Mean+S.E . ) emitted with the PTZ lever prior to 
selection of the-saline lever (10 responses with saline 
lever) on days when saline (1 ml/kg) was injected. 
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selection of the PTZ lever and following saline injection the 
rats emitted 8+2.3 responses with the PTZ lever before selec-
tion of the saline lever. By the thirty-sixth training ses-
sion the rats injected with PTZ emitted 1~0.6 responses with 
the saline lever before PTZ lever selection and following sa-
line injection the rats emitted 3+1.2 responses with the PTZ 
lever before saline lever selection. During acquisition of 
the PTZ-saline discrimination there was a significant {R=0.82 
and 0.91; p< 0.05) decrease in the number of responses emitted 
with the saline lever prior to PTZ lever selection and vice 
versa. During the last ten sessions before generalization 
and antagonism testing began these rats emitted only 2.5 
(+0.44) responses with the saline lever after PTZ injection 
and 3.1 (~0.43) responses with the PTZ lever after saline in-
jection. During subsequent testing the rats continued to 
reliably discriminate between PTZ and saline (Table 3) . 
Effect of Varying Pentylenetetrazol Pretreatment Time on Lever 
Selection in Rats Trained to Discriminate Between Pentylene-
tetrazol and Saline (Table 2) . - One hundred percent of the 
rats selected the PTZ lever when the training dose (20 mg/kg) 
of PTZ was administered 15 min before testing for lever se-
lection. Ninety percent of the rats tested for lever selec-
tion 5 or 30 min after PTZ (20 mg/kg) injection selected the 
PTZ lever and 80% selected the PTZ lever when tested for 
lever selection 60 min following the PTZ injection. When 
tested for lever selection 2 h after PTZ injection 63% of the 
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TABLE 2. Effect of Varying Pentylenetetrazol Treatment Time 
on Lever Selection in Rats Trained to Discriminate 
Pentylenetetrazol from Saline 
Pretreatment Time 1 N2 % Selecting PTZ Lever 3 
5 min 10 90 
15 min 10 100 
30 min 10 90 
60 min 10 80 
2 h 8 63 
4 h 8 13 
24 h 10 0 
1 Rats were injected i.p. with PTZ (20 mg/kg). Following the 
specified pretreatment time the rats were placed in their 
assigned Skinner box and allowed to make a lever selection. 
The lever with which ten responses were completed first was 
considered the selected lever. 
2Nurnber of rats tested. 
3Percent of rats selecting PTZ lever. 
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rats selected the PTZ lever. This was not significantly dif-
ferent (Fisher Exact Probability; p > 0.05), however, from 100% 
PTZ lever selection when lever selection was tested 15 min 
after PTZ (20 mg/kg). In contrast PTZ lever selection 4 or 
24 h after PTZ injection was significantly different (Fisher 
Exact Probability, p< 0.05) from lever selection 15 min after 
PTZ injection as only 13% and none of the rats tested selected 
the PTZ at these times. 
Generalization Testing (Tables 3 and 4) 
1. Anxiogenic CNS Stimulants. 
The training dose of PTZ generalized to lower doses 
of PTZ in a dose dependent (R=0.98, p < .05) manner. Whereas, 
none of the rats selected the PTZ lever following a 2.5 mg/kg 
PTZ injection, 28, 50 and 100% of the rats selected the PTZ 
lever following injection of 5, 10 and 20 mg/kg of PTZ (Table 
3). The ED50 was 8 (5.9-10.8) mg/kg. The rats emitted 
0.3~0.25, 0.5~0.37, 0.7+0.39 and l.1~0.51 responses with the 
nonselected lever prior to lever selection following injec-
tion of 2.5, 5, 10 and 20 mg/kg of PTZ, respectively (Table 3). 
These doses of PTZ did not produce overt convulsions or myo-
clonus which were observed to occur when PTZ (40 mg/kg) was 
administered to naive rats. Following approximately 6 months 
of the PTZ-saline discrimination, however, some of the rats 
began to develop myoclonus after PTZ (20 mg/kg) injection. 
When PTZ (2.5-20 mg/kg) was administered to these rats the 
percentage selecting the PTZ lever was not significantly 
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different (Fisher Exact Probability, p > 0.05) from the percent-
ae of rats selecting the PTZ lever following the acute adminis-
tration of these doses of PTZ. Response rates during test 
sessions when PTZ (2.5-20 mg/kg) was administered were not sig-
nificantly different (One-Way Analysis of Variance, p > 0. 05) 
from the response rates of these rats on the PTZ or saline ses-
sions preceding these tests. 
Following injection of 5, 10 and 20 mg/kg of cocaine O, 
17 and 86% of the rats selected the PTZ lever (R=0.94, p<0.05). 
The ED50 was 13.9 (9.5-20.3) mg/kg. These rats emitted 0.3+ 
0.20, l.5+0.81 and l.7~1.12 responses with the nonselected 
lever prior to lever selection. One rat injected with cocaine 
(20 mg/kg) did not make a lever selection. Response rate 
during the cocaine (5 mg/kg) generalization test was signifi-
cantly greater than (Duncan's Multiple Range Test, p<0.05) 
response rate during the preceding PTZ and saline sessions. 
After cocaine (10 mg/kg) the rats emitted 1046+77 responses. 
This was significantly greater (Duncan's Multiple Range Test, 
p<0.05) than the 806+53 responses emitted during the preced-
ing PTZ session but not significantly different (Duncan's 
Multiple Range Test, p>0.05) from the 1064~66 responses 
emitted the preceding saline session. Following the highest 
dose of cocaine (20 mg/kg) response rate was not significantly 
different (Fd.f. 2,15=3.04, p>0.05) from response rate during 
the preceding PTZ or saline session. 
None of four rats injected with yohirnbine (0.16 mg/kg) 
selected the PTZ lever. One out of five rats selected the 
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PTZ lever after 0.64 mg/kg yohimbine and one out of four rats 
selected the PTZ lever after 10 mg/kg yohimbine. However, 50% 
of twel,ve rats selected the PTZ lever after injection of 2.5 
mg/kg yohimbine. This was significantly different (Fisher Ex-
act Probability, p<0.05) however from 100% PTZ lever selection 
after 20 mg/kg PTZ. During the yohimbine (0.16-10 mg/kg) gen-
eralization tests the rats emitted 3~1.9, 3~1.6, l.7+0.91 and 
3~3.0 responses with the nonselected lever prior to lever se-
lection. Response rate during the 0.16 and 0.64 mg/kg yo-
hirnbine sessions were not significantly different (F d.f. 
2,6=0.44, p>0.05, F d.f. 2,12=1.13, p>0.05) from response rate 
during the PTZ or saline sessions preceding these tests. Re-
sponse rate during the 2.5 mg/kg generalization test was sig-
nificantly lower (Duncan's Multiple Range Test, p <0.05) than 
response rate during the preceding saline session but not sig-
nifidantly different (Duncan's Multiple Range Test, p>0.05) 
from response rate during the preceding PTZ session. During 
the 10 mg/kg yohimbine session response rate was significantly 
lower (Duncan's Multiple Range Test, p<0.05) than response 
rate during the pieceding PTZ and saline sessions. 
None of six rats injected with strychnine (1.25 mg/kg) 
selected the PTZ lever, however, three out of five rats in-
jected with 2.5 mg/kg strychnine selected the PTZ lever. One 
rat did not make a lever selection after injection of the 
highest dose of strychnine. Whereas PTZ lever selection after 
the lowest dose of PTZ was significantly different (Fisher 
Exact Probability, p~0.05) from lever selection after 20 mg/kg 
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PTZ, PTZ lever selection after the highest dose of strychnine 
was not significantly different (Fisher Exact Probability , 
p~0.05) from PTZ lever selection after the training dose of 
PTZ. The rats injected with these doses of strychnine emit-
ted zero and 0.2~0.20 responses with the nonselected lever 
prior to lever selection. Response rates during the strych-
nine (1.25 and 2.5 mg/kg) generalization tests were not sig-
nificantly different (F>d.f. 2,15=3.45, p>0.05; F d.f. 2,12= 
2.76, p 0.05) from response rates during the PTZ or saline 
sessions preceding the tests. 
R05-3663 (0.64-5 mg/kg) dose-dependently (R=0.99, p<0.05) 
generalized to the discriminative stimulus produced by PTZ. 
The ED50 was 2.3 (1.8-2.8) mg/kg. Whereas none of the rats 
selected the PTZ lever following injection of 0.64 mg/kg 
R05-3663, 67 and 100% of the rats selected the PTZ lever fol-
lowing injection of R05-3663 at doses of 2.5 and 5 mg/kg, re-
spectively. During these tests l.3~0.94, 0.5~0.34 and 
l.2+0.80 responses were emitted with the nonselected lever 
prior to lever selection. Response rates during the R05-3663 
(0.64-5 mg/kg) generalization tests were not significantly 
different (F d.f. 2,6=0.52, p>0.05; F d.f. 2,15=3.ll, P>0.05; 
F d.f. 2,15=1.58, p>0.05) from response rates during the PTZ 
or saline sessions preceding the tests. 
2. Non-Anxiogenic Stimulants 
One out of six rats injected with a-amphetamine 
(0.64 lmg/kg) selected the PTZ lever. This was significantly 
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different (Fisher Exact Probability, p<0.05) from 100% PTZ 
lever selection after injection of PTZ (20 mg/kg). These rats 
emitted 0.8~0.54 responses with the nonselected lever prior 
to lever selection. Response rate after this dose of d-ampet-
amine was not significantly different (F d.f. 2,15=1.16, 
p>0.05) from response rate during the PTZ or saline session 
preceding the test. Three rats injected with d-amphetarnine 
(2.5 mg/kg) did not make a lever selection. 
None of the rats injected with methylphenidate (2.5-10 
mg/kg) selected the PTZ lever. All of these rats selected 
the saline lever. Prior to saline lever selection these 
rats emitted 0.5~0.34 and zero responses with the PTZ lever. 
Response rate after methylphenidate (2.5 or 10 mg/kg) was 
not significantly different (F d.f. 2,15=2.31, p>0.05; 
F d.f. 2,9=1.99, p>0.05) from response rate during the pre-
ceding PTZ or saline session. 
None of the rats injected with caffeine (5 and 20 mg/kg) 
selected the PTZ lever, whereas 20% of the rats injected 
with 80 mg/kg of caffeine selected the PTZ lever. PTZ lever 
selection following caffeine was significantly different 
(Fisher Exact Probability, p<0.05) from 100% PTZ lever selec-
tion after PTZ (20 mg/kg). After caffeine injection the rats 
emitted zero, 0.8~0.48 and 0.2~0.20 responses with the non-
selected lever before lever selection. During the caffeine 
(5 or 20 mg/kg) generalization tests response rates were 
not significantly different (F d.f. 2,9=1.30, p>0.05; 
F d.f. 2,9=3.44, p>0.05) from response rates during the pre-
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ceding PTZ saline ses~ions. After caffeine (80 mg/kg) the 
rats emitted 228~73 responses. This was significantly less 
(Duncap's Multiple Range Test, p<0.05) than the 796+121 re-
sponses emitted during the preceding saline session but not 
significantly different (Duncan's Multiple Range Test, p>0.05) 
from the 540+133 responses emitted during the preceding PTZ 
session. 
3. Convulsants 
Bemegride (1.25-5 mg/kg) dose dependently (R=l.00, 
p<0.05) generalized to the PTZ discriminative stimulus. 
Whereas none of the rats selected the PTZ lever after a beme-
gride injection, 50 and 100% selected the PTZ lever after in-
jection of 2.5 and 5 mg/kg bemegride, respectively. The EDSO 
was 2.5 (2.1-2.9) mg/kg. Whereas zero responses were emitted 
with the nonselected lever before lever selection during the 
generalization test with bemegride (1.25 and 2.5 mg/kg), 
0.6~0.33 responses were emitted with the saline lever prior 
to PTZ lever selection during the 5 mg/kg bemegride general-
ization test. Response rates during the bemegride (1.25-5 
mg/kg) generalization test sessions were not significantly 
different (F d.f. 2,6=0.41, p>0.05; F d.f. 2,18=2.87, p>0.05; 
F d.f. 2,15=2.92, p>0.05) from rates of responding during the 
PTZ or saline sessions preceding these tests. 
Fifteen and sixty percent of the rats tested selected 
the PTZ lever following injection of 0.32 and 1.25 mg/kg 
picrotoxin, respectively. This was significantly different 
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(Fisher Exact Probability, p<0.05) however, from 100 percent 
PTZ lever selection following PTZ (20 mg/kg) injection. Dur-
ing th~ picrotoxin generalization tests the rats emitted 
l.1+0.77 and l.0=0.63 responses with the nonselected lever 
prior to lever selection. Response rate following picrotoxin 
(0.32 or 1.25 mg/kg) was not significantly different (F d.f. 
2,18=0.83, p>0.05; F d.f. 2,27=1.60, p> 0.05) from the rate of 
responding during the PTZ or saline session preceding the pi-
crotoxin test. Three rats injected with 2.5 mg/kg picrotoxin 
did not make a lever selection. Higher doses of picrotoxin 
produced convulsions in naive rats and therefore were not 
tested. 
Following injection of 3-mercaptoproprionic acid (5 mg/kg), 
40% of the rats selected the PTZ lever. This was significant-
ly different (Fisher Exact Probability, p<0.05) however from 
100% PTZ lever selection after injection of PTZ (20 mg/kg). 
These rats emitted 1+1.0 responses with the nonselected lever 
prior to lever selection. During the 3-mercaptopropionic acid 
(5 mg/kg) test session the rats emitted 898=94 responses. 
This was significantly greater (Duncan's Multiple Range Test, 
p<0.05) than the 608+50 responses emitted during the preced-
ing PTZ session but not significantly different (Duncan's 
Multiple Range Test, p>0.05) from the 958+84 responses emitted 
during the saline session preceding the test session. Four 
rats injected with a 40 mg/kg dose of 3-mercaptopropionic 
acid died following convulsions produced by the drug. 
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Bicuculline methiodide (1.25-2.5 mg/kg) failed to produce 
PTZ lever selection when administered to the rats trained to 
discrim~nate between PTZ and saline. All of the rats selected 
the saline lever when tested for lever selection after these 
doses of bicuculline. Before saline lever selection these 
rats emitted zero and 0.5+0.50 responses with the PTZ lever. 
Response rates during the bicuculline (1.25 mg/kg and 2.5 
mg/kg) generalization test sessions were significantly differ-
ent (Duncan's Multiple Range Test, p<0.05) from response rates 
during the PTZ sessions preceding the tests but not signifi-
cantly different (Duncan's Multiple Range Test, p>0.05) from 
rate of responding during the preceding saline sessions. 
None of six rats injected with gamma-hydroxybutyrate 
(GHB) at a dose of 160 mg/kg selected the PTZ lever whereas 
17% of the rats selected the PTZ lever following a 320 mg/kg 
GHB injection. The percent PTZ lever selection produced by 
GHB was significantly different (Fisher Exact Probability, 
p<0.05) from 100% PTZ lever selection after PTZ (20 mg/kg). 
Higher doses of GHB are hypnotic and therefore were not tested. 
The rats treated with GHB 160 and 320 mg/kg, respectively, 
emitted 0.2+0.17 and 0.3+0.21 responses with the incorrect 
lever prior to lever selection. Response rate during the 
GHB (160 mg/kg) generalization test was not significantly 
different (F d.f. 2,15=0.90, p>0.05) from response rate dur-
ing the preceding PTZ or saline session, however, during the 
GHB (320 mg/kg) test response rate was significantly dif-
ferent (Duncan's Multiple Range Test, p 0~05) from response 
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rate during the preceding PTZ and saline session. 
Eleven and twenty-five percent of the rats injected with 
nicoti~e, 0.64 a nd 1.25 mg/kg, respectively, selected the PTZ 
lever. This was significantly different (Fisher Exact Prob-
ability, p< 0.05) from 100% PTZ lever selection after PTZ 
(20 mg/kg). One rat injected with nicotine (1.25 mg/kg) did 
not make a lever selection. The rats making a lever selection 
emitted l.3+0.90 and l.6~0.90 responses with the nonselected 
lever prior to lever selection. Response rates during the 
nicotine (0.69 or 1.25 mg/kg) test sessions were not signifi-
cantly different (F.d. f. 2,24=0.92, p>0.05; F. d.f. 2,21=2.33, 
p>0.05) from response rates during the PTZ or saline sessions 
preceding the tests. 
4. Cholinergic Drugs 
None of the rats injected with carbachol (0.32-0.64 
mg/kg) selected the PTZ lever. All of the rats selected the 
saline lever. Prior to lever selection 0.2+0.17 and zero 
responses were emitted with the nonselected lever. Three 
rats injected with 0.64 mg/kg carbachol did not make a lever 
selection. The rats emitted 803+203 responses during the 
carbachol (0.32mg/kg) generalization test. This was signif-
icantly less (Duncan's Multiple Range Test, p<0.05) than the 
1317+52 responses emitted during the preceding saline ses-
sion but not significantly different (Duncan's Multiple 
Range Test, p>0.05) from the 1117~36 responses emitted dur-
ing the preceding PTZ session. 
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Thirty-six percent of eight rats injected with physo-
stigmine (0.64 mg/kg) selected the PTZ lever when this drug 
was administered 30 minutes prior to testing. This was sig-
nificantly different (Fisher Exact Probability, p<0.05) from 
100% PTZ lever selection following injection of PTZ (20 mg/kg). 
Six rats did not make a lever selection. Four rats injected 
with physostigmine (1.25 mg/kg) and tested 30 minutes after 
injection did not make a lever selection. However when tested 
75 minutes after injection, three rats selected the saline 
lever and one rat did not make a lever selection. Zero re-
sponses were made with the nonselected lever prior to lever 
selection in all generalization tests with physostigmine. Re-
sponse rates during the physostigmine (0.64-1.25 mg/kg) gen-
eralization tests were significantly different (Duncan's 
Multiple Range Test, p<0.05) from response rate during the 
PTZ and saline sessions preceding the tests. 
The rats injected with oxotremorine (0.32 mg/kg) selected 
the saline lever and these rats did not emit any responses 
with the PTZ lever before saline lever selection. Three oth-
er rats did not make a lever selection after 0.32 mg/kg oxo-
tremorine. Response rate after oxotremorine was not signif-
icantly different (F d.f. 2,6=2.65, p>0.05) from response 
rate during the preceding PTZ or saline session. 
Thirty-eight percent of eight rats injected with scopol-
amine (0.64 mg/kg) selected the PTZ lever. This was signifi-
cantly different from 100% PTZ lever selection after PTZ 
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(20 mg/kg) (Fisher Exact Probability Test, p<0.05). These 
rats emitted 0.8~0.75 responses with the nonselected lever 
prior t 'o lever selection·. One rat did not make a lever se-
lection. Response rate during the scopolamine (0.64 mg/kg) 
generalization test was significantly less (Duncan's Multiple 
Range Test,<p 0.05) than response rate during the PTZ and sa-
line sessions preceding the scopolamine test. 
5. Drugs Affecting Monoaminergic Activity 
Thirteen and fifty percent of eight rats selected 
the PTZ lever following administration of 0.16 and 0.64 mg/kg 
apomorphine, respectively. The percent PTZ lever sel8ction 
after these doses of apomorphine was significantly different 
(Fisher Exact Probability Test, p<0.05) from 100% PTZ lever 
selection after PTZ (20 mg/kg) . After apomorphine (1.25 
mg/kg) one of two rats selected the PTZ lever and four rats 
did not make a lever selection. Zero, 0.4~0.38 and 0.3 re-
sponses were emitted with the nonselected lever prior to le-
ver selection following these doses of apomorphine. Response 
rate after apomorphine (0.16 mg/kg) was not significantly 
different (F d.f. 2,21=1.85, p>0.05) from response rate dur-
ing the preceding PTZ or saline sessions. After injection 
of 0.64 mg/kg apomorphine, however, response rate was signif-
icantly less JDunc·an'sMultiple Range Test ·, p<0.05) than re-
sponse rate during the preceding saline session but not sig-
nificantly different from response rate during the preceding 
PTZ session (Duncan's Multiple Range Test, p>0.05). 
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Thirty-three percent of six rats injected with proprano-
lol (20 mg/kg) selected the PTZ lever. This was significant-
ly different from 100% PTZ lever selection after PTZ (20 
2 
mg/kg) (X d.F.1=7.87, P ,<0.05). These rats emitted l.0+0.82 
responses with the nonselected lever prior to lever selection. 
Response rate during the propranolol test session was signif-
icantly less (Duncan's Multiple Range Test, p<0.05) than re-
sponse rate during the PTZ and saline session preceding this 
test. 
All of the rats injected with aceperone (0.64 or 2.25 
mg/kg) selected the saline lever and these rats did not emit 
any responses with the PTZ lever before saline lever selec-
tion. These rats were removed from the Skinner boxes after 
lever selection and therefore response rate is not given. 
Twenty-five percent of eight rats selected the PTZ le-
ver after a 100 mg/kg injection of DL-5-hydroxytryptophan 
(5-HTP). This was significantly different (Fisher Exact Pro-
bability, p<0.05) however, from 100% PTZ lever selection af-
ter PTZ (20 mg/kg). These rats emitted 0.3+0.25 responses 
with the nonselected lever before making a lever selection. 
Two rats did not make a lever selection after this dose of 
5-HTP. Response rate after 5-HTP was significantly less 
(Duncan's Multiple Range Test, P<0.05) than rates of respond-
ing during the previous PTZ and saline sessions. 
After fluoxetine (5 mg/kg), 33 percent of six rats se-
lected the PTZ lever and these rats did not emit any re-
sponses with the nonselected lever prior to lever selection. 
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Following injection of a higher (10 mg/kg) dose of fluoxetine, 
two rats selected the saline lever and two rats did not make 
a lever selection . The rats emitted 566~97 responses during 
the fluoxetine (5 mg/kg) generalization test. This was sig-
nificantly less (Duncan's Multiple Range Test, p<0.05) than 
the 1120~82 responses emitted by these rats during the previ-
ous saline session but not significantly different (Duncan's 
Multiple Range Test, p> 0.05) from the 822~76 responses 
emitted during the PTZ session preceding the test. Response 
rate after 10 mg/kg fluoxetine was lower than the preceding 
PTZ and saline sessions but the small number of rats pro-
hibited statistical analysis. 
6. Opiate Agonist and Antagonists 
None of the four rats injected with morphine (2.5 
mg/kg) selected the PTZ lever and these rats did not emit 
any responses with the PTZ lever prior to saline lever se-
lection. Response rate after morphine was not significantly 
different (F d.f.2,6=1.71, p>0.05) from rates of responding 
during the PTZ and saline sessions preceding the morphine 
test. 
Thirty-three percent of six rats injected with naloxone 
(80 mg/kg) selected the PTZ lever and this was significantly 
different (Fisher Exact Probability, p<0.05) from 100% PTZ 
lever selection after PTZ (20 mg/kg), however. These rats 
did not emit any responses with the incorrect lever prior to 
lever selection. One rat did not make a lever selection after 
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TABLE 3 . Generalization tests with rats trained to discriminate between 
pentylenetetrazol (20 mg/kg) and saline.l 
Mean Responses 4 
(+S.E.)with Non-
Selected Lever 
Pretreatment 
Test Drug Dose Time % Selecting 
Before Lever 
(mg/kg) (Minutes) N2 PTZ Lever3 Selection 
ACEPERONE 0.64 30 5 0 0 
2.5 5 0 0 
d-AMPHETAMINE SULFATE 0.64 15 6 17 0.8+0.54 
2.5 6 No Selection 
APOMORPHINE 0.16 15 8 13 0 
HYDROCHLORIDE 0.64 8 50 0.4+0.38 
1. 25 2 50 0.3 
4 No Selection 
BEMEGRIDE 1. 25 15 3 0 0 
2.5 6 50 0 
5 7 100 0.6+0.33 
BICUCULLINE 1. 25 10 6 0 0 
METHIODIDE 2.5 6 0 0.5+0.50 
CAFFEINE CITRATE 5 30 4 0 0 
20 4 0 0.8+0.48 
80 5 20 0.2+0.20 
CARBACHOL 0.32 15 6 0 0.2+0.17 
0.64 1 0 0 
3 No Selection 
COCAINE HYDROCHLORIDE 5 15 6 0 0.3+0.20 
10 6 17 1.5+0 .81 
20 7 86 l.7+1.12 
1 No Selection 
FLUOXETINE 5 15 6 33 0 
10 2 0 1.5 
2 No Selection 
Table 3 continued 
Test Drug 
GAMMA-HYDROXYBUTYRATE 
3-MERCAPTOPROPIONIC 
ACID 
.METHYLPHENIDATE 
MORPHINE SULFATE 
NALOXONE 
HYDROCHLORIDE 
NICOTINE 
OXOTREMORINE 
PENTYLENETETRAZOL 
PHYSOSTIGMINE SULFATE 
PICROTOXIN 
Dose 
(mg/kg) 
160 
320 
10 
40 
2.5 
10 
2.5 
80 
160 
0.64 
1.25 
0. 32 
2.5 
5 
10 
20 
0.64 
1.25 
1.25 
0.32 
1.25 
2.5 
Pretreatment 
Time 
(Minutes) N2 
7 6 
6 
30 5 
4 
15 6 
4 
20 4 
15 6 
1 
3 
15 9 
8 
1 
15 3 
3 
15 4 
14 
14 
14 
30 8 
6 
4 
75 3 
1 
15 7 
10 
3 
% Selecting 
PTZ Lever 
0 
17 
40 
lethal 
0 
0 
0 
33 
No se·lection 
100 
11 
25 
No Selection 
0 
No Selection 
0 
28 
50 
100 
36 
No Selection 
No Selection 
0 
No Selection 
14 
60 
No Selection 
62 
Mean Responses4 
(_±.S.E.)with Non-
Selected Lever 
Before Lever 
Selection 
0.2+0.17 
0.3+0.21 
1.0+1.0 
0.5+0.34 
-0 
0 
0 
a 
1.3+0.90 
l.6+0.90 
0 
0.3+0.25 
0.5+0.37 
0.7+0.39 
l.1+0.51 
0 
0 
1.1+0. 77 
1. o+o .63 
Table 3 continued 
Test Dr\lg 
PROPRANOLOL 
R04-4602 + DL-5-
HYDROXYTRYPTOPHAN 
R05-3663 
SALINE 
SCOPOLAMINE HYDRO-
BROMIDE 
STRYCHNINE SULFATE 
YOHIMBINE 
HYDROCHLORIDE 
Dose 
(mg/kg) 
20 
25 
100 
0.64 
2.5 
5 
0.64 
1. 25 
2.5 
0.16 
0.64 
2.5 
10 
Pretreatment 
Time 
(Minutes) 
30 
60 
30 
30 
63 
4 Mean Responses 
(±_S . E. ) with Non-
% Selecting Selected Lever 
N2 PTZ Lever Before Lever 
Selection 
6 33 i. o+o .02 
8 25 0.3+0.25 
2 No Selection 
4 0 1. 3+0.94 
6 67 0.5+0.34 
-6 100 1. 2+0 .80 
15 14 0 0.4+0.25 
30 8 38 0.8+0.75 
1 No Selection 
15 6 0 0 
5 60 0.2+0.20 
1 No Selection 
30 4 0 3+1.9 
5 20 3+1.6 
12 50 1. 7+0.91 
4 25 3+3.0 
1Following pretreatment with the test drug the rats were placed in their 
assigned Skinner boxes and allowed to make a lever selection. The lever 
with which ten responses were completed first was considered the selected 
lever. 
2 Number of rats tested. 
3 % of rats selecting the pentylenetetrazol lever. "No Selection" indicates 
that 10 responses were not completed with either lever in the 10 min 
session due to behavioral toxicity of the drug. 
4Responses (Mean+S.E.) emitted with nonselected lever before lever selec-
tion. Where N <3 mean is given. 
TABLE 4. Generalization Tests: Effect of test drugs on response rate in rats trained to discriminate 
between pentylenetetrazol (20 mg/kg) and saline. 
Responses/10 Min; Mean+S.E. 3 % + S.E. 4 
Pretreatment 
Test Drug Dose Time Test 
(mg/kg) (Minutes) N2 PTZ 1 Saline Drug % PTZ % Saline 
d-AMPHETAMINE 0.64 15 6 760+66 918+80 898+92 118+5 98+4 
- - - - -
SULFATE 2.5 3 0 0 0 
. 
APOMORPHINE 0.16 15 8 789+45 1033+95 900+114 112+10 74+11 
- -
- -
HYDROCHLORIDE 0.64 8 850+64 1164+59 739+148 86+17 62+12 
- - 78- -1.25 2 1045 1085 830 75 
4 863+96 1085+86 0 0 0 
- -
BEMEGRIDE 1.25 15 3 437+104 523+43 540+57 136+26 80+37 
2.5 6 753+49 967+97 955+55 129+9 102+8 
- - - -
5 7 726+55 965+91 834+60 116+7 91+9 
- - - - -
BICUCULLINE 1. 25 10 6 658+84 1087+35 1038+59 171+22 96+4 
METHIODIDE 2.5 6 623+72 1003+48 977+61 168+22 97+3 
- - -
- -
CAFFEINE CITRATE 5 30 4 428+98 640+247 743+140 198+40 122+10 
20 4 508+65 805+68 785+124 158+23 98+12 
- - -
-
80 5 540+133 796+121 228+73 48+14 28+7 
- - - - -
CARBACHOL 0.32 15 6 1117+36 1317+52 803+203 72+17 59+14 
- -0.64 1 670 690 710 106 103 
3 977+19 1193+28 0 0 0 
- -
COCAINE 5 15 6 923+61 1209+35 1075+47 121+10 88+4 
- -
HYDROCHLORIDE 10 6 806+53 1064+66 1046+77 130+6 99+6 
20 7 843+38 991+74 767+77 93+12 82+13 
- -
- - -
1 890 950 0 0 0 
(J'I 
~ 
TABLE 4 continued 
Responses/10 Min; Mean.:!:_S.E. 3 4 Pretreatment 
-
% + S.E. 
Dose Time 2 Test Test Drug (mg/kg) (Minutes) N PTZ Saline Drug % PTZ % Saline 
FLUOXETINE 5 15 5 822+76 1120+82 566+97 73+12 51+10 
-10 2 970 1110 300 31 28 
2 795 1170 0 0 ,0 
GAMMA- 160 7 6 1050+81 1163+65 1053+55 93+7 89+3 
HYDROXYBUTYRATE 320 5 842+44 1136+60 508+127 58+14 44+10 
-
3-MERCAPTO-
PROPIONIC ACID 10 30 5 608+50 958+84 898+94 148+13 96+10 
- -
- - -
METHYLPHENIDATE 2.5 15 6 938+78 1070+48 1133+66 123+6 106+3 
10 4 928+34 1173+"51 1005+14 107+12 85+10 
- - - -
-
IDRPHINE 2.5 20 3 927+52 933+37 837+32 90+2 90+7 
SULFATE 
NALOXONE 80 15 6 897+87 1093+91 452+152 61+27 44+14 
- -
- -
HYDROCHLORIDE 1 590 670 0 0 0 
160 1 780 1120 510 65 46 
3 1056+119 1183+127 0 0 0 
- -
NICOTINE 0.64 15 9 820+58 971+106 954+88 126+8 112+10 
- -
-
1.25 8 836+75 1040+95 805+80 96+3 79+4 
1 700 860 0 0 0 
OXOTREIDRINE 0.32 15 3 1030+140 1293+32 1223+18 124+18 95+1 
-
3 873+55 1060+72 0 0 0 CTI 
l.11 
TABLE 4 continued 
Response/10 Min; Mean±_S.E. 3 4 % + S.E. 
-Pretreatment 
Dose Time 
N2 
Test 
Test Drug (mg/kg) (Minutes) PTZ Saline Drug % PTZ % Saline 
PENTYLENETETRAWL 2.5 15 4 918+92 1068+122 1105+106 121+7 104+2 
- - -
- -
5 14 691+63 856+67 834+78 106+12 100+4 
10 14 720+39 859+51 825+47 112+7 98+4 
20 14 725+43 847+56 718+45 100+4 88+7 
- - - -
-
PHYSOSTIGMINE 0.64 30 8 815+96 956+98 446+153 56+20 36+14 
- - -SULFATE 1 0 0 0 
1.25 4 0 0 0 
1.25 75 3 1060+15 1277+55 170+95 15+7 14+8 
- - - -
-
1 820 1030 0 0 0 
PICROTOXIN 0.32 15 7 759+78 916+108 924+118 121+11 102+5 
- -
1.25 10 810+59 992+97 829+77 106+11 91+11 
- - -
- -
PROPRANOLOL 20 30 6 858+70 953+70 465+86 54+10 50+9 
R04-4602+DL-5- 25 60 
HYDROXYTRYPTOPHAN 100 30 8 980+89 1103+12 267+39 27+4 24+4 
- - - -2 680 750 0 0 0 
R05-3663 
0.64 30 4 520+147 653+62 667+111 142+35 101+9 
-
2.5 6 433+60 673+83 702+103 163+18 104+9 
- - - -
5 6 396+64 587+140 370+67 92+9 69+10 
- - - -
-
SALINE 15 14 805+49 981+74 1004+70 126+8 104+2 
- - - -
-
(J\ 
(J\ 
TABLE 4 continued 
Test Drug Dose 
(mg/kg) 
SCOPOLAMINE 0.64 
HYDRO BROMIDE 
STRYCHNINE SULFATE 1.25 
2.5 
YOHIMBINE 0.16 
HYDROCHLORIDE 0.64 
2.5 
10 
Pretreatment 
Time 
(Minutes) 
30 
15 
30 
N2 
8 
1 
6 
5 
1 
4 
5 
8 
3 
Response/10 Min; Mean+S.E. 3 
PTZ Saline 
853+54 1173+47 
- -670 910 
818+69 1037+63 
908+"44 1024+51 
- -880 1110 
490+110 600+65 
426+102 600+88 
- -569+40 828+41 
556+145 853+213 
Test 
Drug 
479+125 
-0 
1032+69 
620+206 
-0 
567+72 
438+84 
643+75 
117+92 
4 % + S.E. 
% PTZ % Saline 
55+13 33+10 
- -0 0 
129+13 100+5 
68+21 62+20 
- -0 0 
129+30 94+2 
114+15 72+9 
-112+9 67+6 
18+11 18+15 
1Test drugs were administered intraperitoneally. Following pretreatment with the test drugs the rats 
were placed in their assigned Skinner box and allowed to respond with the levers for 10 min. 
2Number of rats tested. 
3Total responses (Mean.:t_S.E.) emitted during the 10 min session following test drug treatment and 
during the preceding pentylenetetrazol (20 mg/kg) and saline session. 
4values were obtained by dividing the total number of lever presses emitted following test drug by 
the total number of responses during the preceding pentylenetetrazol (20 mg/kg) and saline session. 
CTI 
-.J 
68 
this dose of naloxone. After naloxone (160 mg/kg), one rat 
selected the PTZ lever and three rats did not make a lever 
selection. Response rate after naloxone (80 mg/kg) was sig-
nificantly less (Duncan's Multiple Range Test, p<0.05) than 
the response rate during the PTZ and saline sessions preced-
ing the naloxone test. 
Antagonism Testing (Tables 5 and 6) 
1. Effect of Benzodiazepines, Meprobamate and Barbitur-
ates 
Pretreatment of rats trained to discriminate PTZ 
(20 mg/kg) from saline with either saline or 86% saline, 1% 
Tween and 13% propylene glycol failed to antagonize the dis-
criminative stimulus produced by PTZ. All of the rats pre-
treated with the solvents selected the PTZ lever. Rats pre-
treated with saline emitted 0.5~0.37 responses with the sa-
line lever prior to PTZ lever selection whereas rats pre-
treated with 86% saline 1% Tween 80 and 13% ·propylene glycol 
emitted 0.3+0.29 responses with the saline lever before PTZ 
lever selection. Rate of responding during the saline antag-
onism test was not significantly different (F d.f. 2,39=0.38, 
p>0.05) from response rate during the PTZ or saline session 
preceding the test. Response rate after 86% saline, 1% Tween 
80 and 13% propylene glycol treatment however, was signifi-
cantly less (Duncan's Multiple Range Test, p<0.05) than re-
sponse rate during the preceding saline session but not sig-
nificantly different (Duncan's Multiple Range Test, p>0.05) 
from response rate during the preceding PTZ session. 
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Pretreatment with chlordiazepoxide (0.64-10 mg/kg) pro-
duced a dose-dependent (R=0.93, p<0.05) antagonism of discri-
minativ~ stimulus produced by PTZ. WHereas 80% of the rats 
pretreated with chlordiazepoxide (CDP) at a dose of 0.64 
mg/kg 30 minutes before PTZ (20 mg/kg) injection selected the 
PTZ lever, 30 and 20% of the rats selected the PTZ lever af-
ter pretreatment with 2.5 and 10 mg/kg CDP. The ED50 was 1.8 
(0.67-4.96) mg/kg. The rats pretreated with CDP (0.64 mg/kg) 
emitted 0.4~0.22 responses with the nonselected lever prior 
to lever selection whereas the rats pretreated with CDP (2.5 
or 10 mg/kg) did not emit any responses with the nonselected 
lever prior to lever selection. Response rate during the CDP 
(8.64-10 mg/kg) antagonism test was not significantly differ-
ent (One-Way Analysis of Variance, p>0.05) from rates of re-
sponding during the saline or PTZ sessions preceding the 
tests. 
Clonazepam (0.04-0.64 mg/kg) pretreatment antagonized 
the discriminative stimulus produced by PTZ in a dose-depend-
ent (R=0.96, p<0.05) manner. Whereas 50% of teh rats pre-
treated with clonazepam at a dose of 0.04 mg/kg 30 minutes 
prior to PTZ (20 mg/kg) selected the PTZ lever, 38 and 0% of 
the rats pretreated with clonazepam (0.16 and 0.64 mg/kg) se-
lected the PTZ lever. The ED50 was 0.05 (0.015-0.17) mg/kg. 
The rats pretreated with clonazepam (0.04 mg/kg) emitted 
0.2+0.16 responses with the nonselected lever prior to lever 
selection whereas the rats pretreated with 0.16 and 0.64 
mg/kg of clonazepam did not emit any responses with the non-
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selected lever prior to lever selection. Response rates of 
rats pretreated with clonazepam (0.04 mg/kg) were signifi-
cantly greater (Duncan's Multiple Range Test, p<0.05) than 
rates of responding during the preceding saline session but 
not significantly different (Duncan's Multiple Range Test, 
P>0.05) from rates of responding during the preceding PTZ 
session. Response rates after clonazepam (0.16 and 0.64 
mg/kg) pretreatment, however, were not significantly differ-
ent (F d.f. 2,15=1.45, p>0.05; F d.f. 2,15=1.94, p>0.05) from 
rates of responding during the preceding PTZ or saline ses-
sions. 
Diazepam (1.25-10 mg/kg) injection 30 minutes prior to 
administration of PTZ (20 mg/kg) produced a dose-dependent 
(R=0.99, p<0.05) antagonism of the discriminative stimulus 
produced by PTZ (20 mg/kg). Whereas 83% of the rats pre-
treated with diazepam (1.25 mg/kg) selected the PTZ lever, 
67, 33 and 17% of the rats selected the PTZ lever after pre-
treatment with 2.5, 5 and 10 mg/kg of diazepam. The ED50 
was 3.5 (1.6-8.0) mg/kg. These rats emitted 0.8+0.54, 
l.5~1.33, 0.7~0.49 and 2.0+0.77 responses with the nonse-
lected lever prior to lever selection after pretreatment with 
diazepam 1.25, 2.5, 5 and 10 mg/kg, respectively. Response 
rate during the diazepam (1.25 mg/kg) antagonism test was 
significantly less (Duncan's Multiple Range Test, p<0.05) 
than rates of responding during the preceding saline session 
but not significantly different (Duncan's Multiple Range Test, 
p>0.05) from rates of responding during the preceding PTZ 
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session. Rates of responding after diazepam (2.5 and 5 mg/kg) 
pretreatment were not significantly different (F d.f. 2,6=0.47, 
P>0.05~ F d.f. 2,15=1.60, P>0.05) from rates of responding 
during the saline or PTZ sessions preceding tests with these 
doses of diazepam. However, rates of responding after pre-
treatment with the highest dose of diazepam (10 mg/kg) were 
significantly less (Duncan's Multiple Range Test, P<0.05 than 
rates of responding during the preceding PTZ and saline ses-
sions. 
Clobazam (0.64-40 mg/kg) 30 minutes prior to PTZ (20 
mg/kg) antagonized the discriminative stimulus produced by 
PTZ in a dose-dependent manner (R=0.99, P<0.05). Whereas 
100% of the rats pretreated with clobazam (0.64 mg/kg) se-
lected the PTZ lever, 83, 33 and 0% of the rats selected the 
PTZ lever after treatment with 2.5, 10 and 40 mg/kg clobazam, 
respectively. The ED50 was 6.2 (2.4-16.0) mg/kg. The rats 
pretreated with clobazam (0.64 and 2.5 mg/kg) did not emit 
any responses with the nonselected lever prior to lever se-
lection whereas the rats pretreated with 10 and 40 mg/kg 
clobazam emitted 0.2~0.17 responses with the nonselected 
lever prior to lever selection. Response rates during the 
clobazam (2.5 and 40 mg/kg) antagonism tests were not sig-
nificantly different (F d.f. 2,5=1.61, p>0.05; F d.f. 2,9= 
2.05, p>0.05) from rates of responding during the saline or 
PTZ sessions preceding the tests. Response rates after 
clobazam (10 mg/kg) was significantly less (Duncan's Mul-
tiple Range Test, p<0.05) than rate of responding during 
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the preceding saline session but not significantly different 
(Duncan's Multiple Range Test, p>0.05) from rates of respond-
ing du~ing the preceding PTZ session. 
Flurazepam (1.25-20 mg/kg) antagonized the PTZ discrimi-
native stimulus in dose-dependent fashion (R=0.96, p<0.05). 
Whereas 100% of the rats pretreated with flurazepam (1.25 
mg/kg) 30 minutes before PTZ (20 mg/kg) selected the PTZ 
lever, 50 and 33% of the rats selected the PTZ lever after 
pretreatment with 5 and 20 mg/kg flurazepam. The ED50 was 
8.6 (3.1-13.7) mg/kg. The rats pretreated with flurazepam 
emitted 0.3+0.25, 0.2~0.17 and zero responses with the non-
selected lever prior to lever selection after 1.25, 5 and 20 
mg/kg flurazepam, respectively. Rate of responding of rats 
pretreated with flurazepam (1.25 mg/kg) was significantly 
greater (Duncan's Multiple Range Test, p<0.05) than rate of 
responding during the preceding saline session but not sig-
nificantly different (Duncan's Multiple Range Test, p>0.05) 
from response rate during the preceding PTZ session. After 
flurazeparn (5 mg/kg) pretreatment the rats emitted 963~78 re-
sponses. This was not significantly different (F.d. f .2,15= 
1.36, p>0.05) from the 1105+57 emitted during the preceding 
saline session or the 963~74 responses that were emitted dur-
ing the preceding PTZ sessions. Response rate after fluraze-
pam (20 mg/kg) pretreatment, however, was significantly less 
(Duncan's Multiple Range Test, p<0.05) than rate of respond-
ing during the preceding PTZ and saline sessions. 
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Meprobamate (5-80 mg/kg) antagonized the PTZ discrimina-
tive stimulus in a dose-dependent (R=0.98, p<0.05) manner. 
Whereas 100% of the rats treated with meprobamate (5 mg/kg) 
30 minutes prior to PTZ (20 mg/kg) selected the PTZ lever, 
67 and 0% of the rats injected with meprobamate 20 and 80 
mg/kg selected the PTZ lever. The ED50 was 22.5 (16.6-30.7 
mg/kg. The rats treated with meprobamate 5 and 80 mg/kg 
emitted 0.2+0.17 responses with the nonselected lever prior 
to lever selection whereas the rats treated with 20 mg/kg 
meprobamate did not emit any responses with nonselected le-
ver before lever selection. Response rates after meproba-
mate (5-80 mg/kg) pretreatment were significantly less (Dun-
can's Multiple Range Test, p<0.05) than rates of responding 
during the preceding saline sessions but not significantly 
different (Duncan's Multiple Range Test, p>0.05) from re-
sponse rates during the preceding PTZ sessions. 
Pentobarbital (2.5-10 mg/kg) pretreatment dose-depend-
ently (R=0.98, p<0.05) antagonized the discriminative stimu-
lus produced by PTZ (20 mg/kg). Whereas 100% of the rats 
treated with pentobarbital (2.5 mg/kg) 30 minutes before PTZ 
(20 mg/kg) selected the PTZ lever, 33 and 0% selected the 
PTZ lever after pretreatment with 5 and 10 mg/kg pentobarbi-
tal, respectively. These rats emitted 2.0+l.98 zero and 
0.9+0.80 responses with the nonselected lever prior to lever 
selection after pretreatment with pentobarbital. Response 
rates during the pentobarbital (2.5-10 mg/kg) test sessions 
were not significantly different (F d.f. 2,15=3.21, p>0.05; 
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F d.f. 2,15=0.0l, p>0.05; F d.f. 2,15=0.76, p>0.05) from 
rates of responding during the saline or PTZ sessions preced-
ing the pentobarbital antagonism tests. 
Phenobarbital (2.5-40 mg/kg) treatment .30 minutes prior 
to PTZ (20 .:mg/kg) produced a dose-dependent (R=l.00, p<0.05) 
antagonism of the PTZ discriminate stimulus. Whereas 100% 
of the rats pretrreated with 2.5 mg/kg phenobarbital selected 
the PTZ lever, 50 and 0% of the rats pretreated with 10 and 
40 mg/kg phenobarbital selected the PTZ lever. The ED50 was 
10 (7.4-13.5) mg/kg. The rats pretreated with 2.5 and 40 
mg/kg phenobarbital emitted 0.7~~.42 responses with the non-
selected lever before lever selection whereas the rats pre-
treated with 10 mg/kg phenobarbital emitted zero responses 
with the nonselected lever prior to lever selection. Rates 
of responding after pretreatment with phenobarbital (2.5 and 
10 mg/kg) were not significantly different (F d.f. 2,12=1.43, 
p>9.05, F d.f. 2,12=3.29, p>0.05) from rates of responding 
during the PTZ or saline sessions preceding these phenobarbi-
tal antagonism tests. After pretreatment with 40 mg/kg 
phenobarbital the rats emitted 632+91 responses. This was 
significantly less (Duncan's Multiple Range Test, p<0.05) 
than 966+63 responses that were emitted during the preceding 
saline session but not significantly different (Duncan's 
Multiple Range Test, p 0.05)>from 778+94 responses emitted 
during the preceding PTZ session. 
2. Effect of Non-Anxiolytic Anticonvu1s·ant Drugs 
Trimethadione (TMD) failed to significantly (Fisher 
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Exact Probability, P>0.05) antagonize the discriminative stim-
ulus produced by PTZ. Seventy-eight percent of the rats pre-
treate~ with TMD (160 mg/kg) selected the PTZ lever when TMD 
was administered 30 minutes before PTZ (20 mg/kg) and 67% of 
six rats selected the PTZ lever after 320 mg/kg TMD pretreat-
ment. Two rats pretreated with the latter dose of TMD did 
not make a lever selection. After TMD 160 and 320 mg/kg pre-
treatment the rats making a lever selection emitted 0.3+0.24 
and 2.0~l.29 responses, respectively, with the nonselected 
lever prior to lever selection. On the TMD (160 mg/kg) test 
session the rats emitted 553+54 responses. This was signif-
icantly less (Duncan's Multiple Range Test, p<0.05) than the 
803~71 responses emitted during the preceding saline session 
but not significantly different (Duncan's Multiple Range 
Test, p>0.05) from 623~75 responses emitted during the pre-
ceding PTZ session. During the TMD (320 mg/kg) test ses-
sion, however, rate of responding was significantly less 
(Duncan's Multiple Range Test, P<0.05) than response rate 
during the preceding PTZ and saline sessions. 
Ethosuximide (100-200 mg/kg) treatment 30 minutes prior 
to injection of PTZ (20 mg/kg) failed to significantly 
(Fisher Exact Probability, p>0.05) antagonize the PTZ dis-
criminative stimulus. Seventy-eight percent of the rats 
pretreated with ethosuximide (100 mg/kg) selected the PTZ 
lever and 100% of the rats injected with 200 mg/kg ethosuxi-
mide selected the PTZ lever. Two rats pretreated with the 
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highest dose of ethosuximide did not make a lever selection . 
The rats pretreated with 100 mg/kg ethosuximide emitted 0.9+ 
0.51 responses with the nonselected lever prior to lever se-
lection, whereas the rats pretreated with 200 mg/kg ethosuxi-
mide that made a lever selection emitted 0.4~0.29 responses 
with the saline lever prior to PTZ lever selection. Response 
rates during the ethosuximide (100 and 200 mg/kg) test ses-
sions were significantly less (Duncan's Multiple Range Test, 
p<0.05) than rates of responding during the preceding PTZ 
and saline sessions. 
Diphenylhydantoin (30-60 mg/kg) administered 15 minutes 
before injection of PTZ (20 mg/kg) failed to significantly 
(Fisher Exact Probability, p>0.05) antagonize the PTZ dis-
criminative stimulus. Eighty-three percent of the rats pre-
treated with either 30 or 60 mg/kg diphenylhydantoin (DPH) 
selected the PTZ lever. Zero and 0.2~0.17 responses were 
emitted with the nonselected lever prior to lever selection 
during the test sessions when the rats were pretreated with 
30 and 60 mg/kg (DPH), respectively. Response rates during 
the antagonism test sessions were significantly less (Dun-
can's Multiple Range Test, p<0.05) than response rates dur-
ing the saline and PTZ sessions preceding the tests. 
3. Effect of Some GABAmimetic Drugs 
Treatment of rats trained to discriminate PTZ (20 
mg/kg) from saline with valproic acid (40-320 mg/kg) pro-
duced a dose-dependent (R=0.98, p<0.05) antagonism of PTZ 
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discriminative stimulus. Whereas 100% of the rats treated 
with valproic acid (40 mg/kg) selected the PTZ lever, 75 and 
33% of . the animals selected the PTZ lever after pretreatment 
with 160 and 320 mg/kg valproic acid, respectively. The EDSO 
was 244 (156-382) mg/kg. Three rats pretreated with 640 mg/kg 
valproic acid did not make a lever selection. Rats pre-
treated with 40 mg/kg valproic acid did not emit any responses 
with the saline lever prior to PTZ lever selection whereas the 
rats pretreated with 160 and 320 mg/kg valproic acid emitted 
0.4+0.26 and 0.7±0.49 responses with the incorrect lever prior 
to lever selection. Rats pretreated with valproic acid (160 
mg/kg) emitted 600±59 responses during this valproic acid 
test session. This was significantly less (Duncan's Multiple 
Range Test, p<0.05) than 903±80 responses emitted during the 
preceding saline session but not significantly different 
(Duncan's Multiple Range Test, p>0.05) from 614±80 responses 
emitted during the preceding PTZ session. Response rate dur-
ing the valproic acid (320 mg/kg) test session, however, was 
significantly less (Duncan's Multiple Range Test, p<0.05) 
than rates of responding during the preceding PTZ and saline 
sessions. 
Administration of etomidate sulfate (5 -mg/k.g) 5 minutes 
before injection of PTZ (20 mg/kg) failed to significantly 
(Fisher Exact Probability, p>0.05} antagonize the PTZ dis-
criminative stimulus. Eighty-three percent of the rats 
treated with this dose of etomidate selected the PTZ lever. 
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The rats pretreated with etomidate (5 mg/kg) emitted l.2~1.17 
responses with the nonselected lever prior to lever selection. 
Five o~t of six rats treated with etomidate (10 mg/kg) 5 min-
utes before PTZ (20 mg/kg) did not make a lever selection. The 
one rat that made a lever selection selected the PTZ lever and 
emitted one response with the saline lever before PTZ lever 
selection. The rats emitted 793~77 responses during the etomi-
date (5 mg/kg) test session. This was significantly less 
(Duncan's Multiple Range Test, p<0.05) than 1087+50 responses 
emitted during the preceding saline session but not signifi-
cantly different (Duncan's Multiple Range Test, p>0.05) from 
810+49 responses ewitted during the preceding PTZ session ~ . 
Treatment of rats with etomidate (10 and 40 mg/kg) two 
hours before PTZ (20 mg/kg) injection also failed to antago-
nize the discriminative stimulus produced by PTZ. All of 
the rats pretreated with 10 mg/kg etomidate and tested 2 
hours later for lever selection selected the PTZ lever. These 
rats emitted 0.8+0.48 responses with the saline lever before 
PTZ lever selection. Response rate during this test session 
was significantly different (Duncan's Multiple Range Test, 
p 0~05) from rates of responding during the preceding PTZ and 
saline sessions. After a 40 mg/kg etomidate injection two 
out of four rats selected the PTZ lever and two selected the 
saline lever. This was not significantly different (Fisher 
Exact Probability, p>0.05) from 100% PTZ lever selection 
after PTZ (20 mg/kg). These rats emitted 2.0+1.68 responses 
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with the nonselected lever prior to lever selection. Two rats 
did not make a lever selection after pretreatment with 40 
mg/kg etomidate. Response rate during the etomidate (40 mg/ 
kg) test session was significantly different (Duncan's Mul-
tiple Range Test, p<0.05) from response rates during the pre-
ceding PTZ and saline sessions. 
Garnrna-hydroxybutyrate (GHB) treatment 7 minutes prior to 
PTZ (20 mg/kg) injection failed to antagonize the PTZ dis-
criminative stimulus. One hundred percent of the rats pre-
treated with GHB (80-160 mg/kg) selected the PTZ lever. 
These rats emitted l.3+0.95 and 0.5+0.29 responses with the 
saline lever before PTZ lever selection. Response rates dur-
ing the GHB antagonism tests were not significantly different 
(F d.f. 2,9=1.65, p>0.05; F d.f. 2,9=1.86, p>0.05) from re-
sponse rates during the PTZ and saline sessions preceding 
these tests. Four rats pretreated with 320 mg/kg GHB did 
not make a lever selection. 
Administration of garnma-acetylenic GABA (100 mg/kg) 2-24 
hours prior to PTZ (20 mg/kg) injection did not significantly 
(Fisher Exact Probability, p<0.05) antagonize the discrimina-
tive stimulus produced by PTZ. When tested for lever selec-
tion 2, 4, 8 and 24 hours after gamma-acetylenic GABA (GAG), 
80, 100, 100 and 86% of the rats making a lever selection se-
lected the PTZ lever. These rats emitted zero, 0.4~0.40, 
0.5+0.50 and l.4+0.81 responses with the nonselected lever 
prior to lever selection. Response rates during all GAG 
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antagonism tests were significantly lower (Duncan's Multiple 
Range T~st, p<0.05) than response rates during the PTZ and 
saline ·sessions preceding these tests. One, two and four rats 
tested for lever selection at four, eight and 24 hours after 
GAG did not make a lever selection. 
Gamma vinyl GABA (1000 mg/kg) did not angagonize the 
PTZ discriminative stimulus when the rats were tested for le-
ver selection 72 hours after gamma-vinyl GABA (GVG) injection. 
Three out of four rats tested at this time selected the PTZ 
lever and these rats did not emit any responses with the sa-
line lever before PTZ lever selection. One rat did not make 
a lever selection. When tested at 2 and 8 hours after GVG 
the rats did not make a lever selection. One rat selected 
the PTZ lever when tested 24 hours after GVG, seven rats did 
not make a lever selection. Response rate for the three rats 
making a lever selection 72 hours after GVG was significantly 
less (Duncan's Multiple Range Test, p<0.05) than the rate of 
responding of these rats during the preceding PTZ and saline 
sessions. 
4. Other CNS Depressants 
Ethanol (250-1000 mg/kg) treatment 15 minutes prior 
to injection of PTZ (20 mg/kg) failed to antagonize the dis-
criminative stimulus produced by PTZ. All of the rats pre-
treated with ethanol selected the PTZ lever and these rats 
did not emit any responses with the saline lever before PTZ 
lever selection. Two rats pretreated with 1000 mg/kg ethanol 
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did not make a lever selection. Response rates during the 
ethanol test sessions were significantly less (Duncan's Mul-
tiple Range Test, P<0.05) than rates of responding during the 
saline sessions preceding the tests but not significantly dif-
ferent (Duncan's Multiple Range Test, p~ 0.05) from response 
rates during the PTZ sessions preceding the tests. 
Morphine (10 mg/kg) pretreatment did not antagonize the 
PTZ discriminative stimulus when administered 15 minutes 
prior to PTZ (20 mg/kg). Three of eight rats that made a 
lever selection selected the PTZ lever and these rats emitted 
0.7~0.67 responses with the saline lever prior to PTZ lever 
selection. Response rate during the morphine antagonism test 
session was significantly less (Duncan's Multiple Range Test, 
p<0.05) than rate of responding during the preceding PTZ and 
saline sessions. 
5. Effect of Caffeine: A Phosphodi~sterase Inhibitor 
Eighty percent of five rats treated with caffeine 
(20 mg/kg) 30 minutes before PTZ (20 mg/kg) injection selected 
the PTZ lever (Fisher Exact Probability, p >0.05). These rats 
emitted 0.4~0.24 responses with the nonselected lever prior 
to lever selection. Response rate during the caffeine antag-
onism test session was not significantly different (F.d. 
f.2,9=1.05, p>0.05) £rom rate 0£ responding during the pre-
ceding PTZ or saline sessions. 
6. Effect 0£ Drugs A££ecting Catec·holaminergic Trans-
mission. 
Clonidine (0.04-0.64 mg/kg) treatment 30 minutes 
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before injection of PTZ (20 mg/kg) failed to antagonize the 
discriminative stimulus produced by PTZ. All of the rats 
pretreated with these doses of clonidine selected the PTZ 
lever. Three rats pretreated with 0.64 mg/kg clonidine did 
not make a lever selection. After 0.04 mg/kg pretreatment 
the rats emitted 0.8~0.75 responses with the saline lever be-
fore PTZ lever selection and after 0.16 mg/kg clonidine pre-
treatment the rats emitted l.8~0.97 responses with the sa-
line lever be£ore PTZ lever selection. Response rates dur-
ing the clonidine test sessions were significantly less 
(Duncan's Multiple Range Test, P<0.05) than the rate 0£ re-
sponding during the PTZ and saline sessions preceding the 
clonidine antagonism tests. 
Propranolol (10 mg/kg) pretreatment did not signi£icant-
ly (Fisher Exact Probability, p~~ .. 05) antagonize the PTZ dis-
criminative stimulus. Eighty percent of five rats pretreated 
with propranol selected the PTZ lever and these rats did not 
emit any responses with the nonselected leve~ prior to lever 
selection. During the propranol test session the rats emit-
ted 588+121 responses. This was significantly less (Duncan's 
Multiple Range Test, p<0.05) than the 1008~66 responses 
emitted during the saline session preceding the test but not 
significantly di£ferent (Duncan's Multiple Range Test, p>0.05) 
from 668+97 responses emitted during the PTZ preceding the 
test. 
Aceperone (0.64 or 2.5 mg/kg) did not antagonize the PTZ 
discriminative stimulus. All of four rats pretreated with 
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Haloperidol (0.16-0.64 mg/kg) also failed to antagonize 
the discriminative stimulus produced by PTZ. ALl of six rats 
treatep with haloperidol (0.16 mg/kg) 30 minutes prior to PTZ 
(20 mg/kg) injection selected the PTZ lever. These rats 
emitted 0.4+0.33 responses with the saline lever before se-
lection of the PTZ lever. During the haloperidol (0.16 mg/kg) 
test session the rats emitted 265~97 responses. This was sig-
nificantly less (Duncan's Multiple Range Test, p<0.05) than 
the 975+86 and 1132+71 responses that were emitted during the 
PTZ and saline sessions preceding the haloperidol antagonism 
test. 
Of two rats pretreated with 0.64 mg/kg haloperidol, one 
rat did not make a lever selection and the other rat selected 
the PTZ lever. 
7. Effect of Drugs Affecting Serotonergic Transmission 
Five rats treated with methysergide (2.5 mg/kg) 30 
minutes before injection of PTZ (20 mg/kg) selected the PTZ 
lever. These rats emitted 3.4+1.67 responses with the saline 
lever before PTZ lever selection. Response rate during the 
methysergide antagonism test session was significantly dif-
ferent (Duncan's Multiple Range Test, p<0.05) from response 
rate during the saline session preceding the test but not 
significantly different (Duncan's Multiple Range Test, p>0.05) 
from response rate during the PTZ session preceding the test. 
Fluoxetine (5-10 mg/kg) treatment 15 minutes before in-
jection of PTZ · (20 mg/kg) failed to antagonize the discrimi-
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native stimulus produced by PTZ. All of the rats pretreated 
with these doses of fluoxetine selected the PTZ lever and 
these rats did not emit any responses with the saline before 
selection of the PTZ lever. Response rate during the fluoxe-
tine antagonism test sessions were significantly less (Dun-
can's Multiple Range Test, p<0.05) than response rate during 
the PTZ and saline sessions preceding the tests. 
Amitriptyline (10-20 mg/kg) injection 30 minutes before 
PTZ (20 mg/kg) did not block the PTZ discriminative stimulus. 
All of six rats pretreated with 10 mg/kg amitriptyline se-
lected the PTZ lever and these rats emitted l.8+0.87 re-
sponses with the saline lever before PTZ lever selection. 
These rats emitted 213±75 responses during this amitriptyline 
test session. This was significantly less (Duncan's Multiple 
Range Test, p<0.05) than the 410±72 and 853±80 responses that 
were emitted during the PTZ and saline sessions preceding the 
tests. After 20 mg/kg amitriptyline pretreatment three rats 
did not make a lever selection while two selected the PTZ 
lever. The two rats that made a lever selection emitted an 
average of one response on the saline lever before selection 
of · the PTZ lever. Response rate of these two rats appeared 
to be decreased compared to response rate during the PTZ and 
saline sessions preceding the test. 
Treatment with R04-4602 plus DL-5-hydroxytryptophan 
(100 mg/kg) one hour before PTZ (20 mg/kg) injection did not 
antagonize the discriminative stimulus produced by PTZ. All 
of the rats pretreated with R04-4602 plus DL~S-hydroxytryp-
86 
tophan (5-HTP) selected the PTZ lever and these did not emit 
any responses with the saline lever before selection of the 
PTZ lever. Response rate during the 5-HTP antagonism test 
session was significantly less (Duncan's Multiple Range Test, 
p<0.05) than response rate during the PTZ and saline sessions 
preceding the R04-4602 + 5-HTP tests. 
8. Effect of Anticholinergics 
Scopolamine (0.64 mg/kg) treatment 15 minutes before 
injection of PTZ (20 mg/kg) did not significantly (Fisher 
Exact Probability, p>0.05) antagonize the PTZ discriminative 
stimulus. Eighty-four percent of six rats selected the PTZ 
lever while one rat did not make a lever selection. The rats 
that made a lever selection emitted l.0~0.63 responses with 
the nonselected lever prior to lever selection. During the 
scopolamine antagonism test the animals emitted 124+70 re-
sponses. This was significantly less (Duncan's Multiple 
Range Test, p<0.05) than the 906+67 and 1166+54 responses 
that were emitted during the PTZ and saline sessions preced-
ing the test. 
Atropine (5-10 mg/kg) also failed to antagonize the PTZ 
discriminative stimulus. All of four rats treated with 5 
mg/kg atropine 30 minutes before injection of pTZ (20 mg/kg) 
selected the PTZ lever and these rats did not emit any re-
sponses with the saline lever before PTZ lever selection. 
Response rate of these rats during the test session was sig-
nificantly less (Duncan's Multiple Range Test, p<0.05) than 
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TABLE 5. Antagonism tests with rats trained to discriminate between 
pentylenetetrazol (20 mg/kg) and saline. l 
4 Mean Responses ~· 
(+S.E.)on Non-
Pretreatment Selected Lever 
Dose Time 2 % Selecting Before Lever Test Drug (mg/kg) (Minutes) N PTZ Lever3 Selection 
ACEPERONE 0.64 30 4 100 0.75+0.75 
2.5 5 80 0.20+0.20 
AMITRIPTYLINE 10 30 6 100 1.8+0 .87 
HYDROCHLORIDE 20 2 100 1.0 
3 No Selection 
ATROPINE SULFATE 5 30 4 100 0 
1 No Selection 
10 2 100 0.5 
CAFFEINE CITRATE 20 30 5 80 0.4+0.24 
CHLORDIAZEPOXIDE 0.64 30 10 80 0.4+0.22 
-
HYDROCHLORIDE 2.5 10 30 0 
10 10 20 0 
CHLORPROMAZI NE 1. 25 30 4 100 0 
5 4 No Selection 
CLOBAZAM 0.64 30 6 100 0 
2.5 6 83 0 
10 6 33 0.2+0.17 
40 5 0 0.2+0.17 
CLONAZEPAM 0.04 30 6 50 0.2+0.16 
0.16 6 33 0 
0.64 8 0 0 
CLONIDINE 0.04 30 4 100 0.8+0.75 
HYDROCHLORIDE 0.16 5 100 1.8+0. 97 
0.64 1 100 0 
3 No Selection 
DIAZEPAM 1.25 30 6 83 0.8+0.54 
2.5 6 67 1. 5+1. 33 
5 6 33 0.7+0.49 
10 6 17 2. o+o. 77 
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TABLE 5 continued 
4 
Mean Responses 
( +S .E.) on Non-
Pretreatment Selected Lever 
Dose Time 2 
% Selecting Before Lever 
Test Drug (mg/kg) (Minutes) ... N -PTZ -Lever3 . SeJ.~ct;i.on 
DIPHENYLHYDAN'IDIN 30 15 6 83 0 
60 6 83 0.2+0.17 
ETHANOL 250 15 3 100 0 
1000 4 100 0 
2 No Selection 
ETHOSUXIMIDE 100 30 9 78 0;9+0.51 
200 5 100 0.4+0.24 
2 No Selection 
ETOMIDATE SULFATE 5 5 6 83 l.2+1.17 
10 1 100 1.0 
5 No Selection 
10 2 h 4 100 0.8+Q.48 
40 4 50 2;0+1.68 
2 No Selection 
FLUOXETINE 5 15 3 100 0 
10 4 100 0 
FLURAZEPAM 1.25 30 0.3+0.25 DI HYDROCHLORIDE 6 100 5 6 50 0.2+0.17 
20 6 33 0 
GAMMA-ACETYLENIC 100 2 h 5 80 0 
GAMA 4 h 5 100 OA+0.40 
1 100 0.5+0.50 
8 h 4 100 0.5+0.50 
2 No Selection 
24 h 7 86 1.4+0 .81 
4 No Selection 
GAMMA-HYDROXY- 80 7 4 100 1-. 3+0. 95 
BUTYRATE 160 4 100 0~5+0.29 
320 4 No Selection 
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TABLE 5 continued 
4 Mean Responses 
( +S .E.) on Non-
Pretrea trnent Selected Lever 
Dose Time 2 % Selecting Before Lever Test Drug (mg/kg) (Minutes) N PTZ Lever3 Selection 
GAMMA-VINYL GABA 1000 2 4 No Selection 
8 4 No Selection 
24 1 100 0 
7 No Selection 
72 3 100 0 
1 No Selection 
HALOPERIDOL 0.16 45 6 100 0.4+0.33 
0.64 1 100 0 
1 No Selection 
MEPROBAMA'J'E 5 30 6 100 0.2+0.17 
20 6 67 0 
80 6 0 0.2+0.17 
METHYSERGIDE 2.5 30 5 100 3.4+1.67 
MORPHINE SULFATE 10 15 3 100 0.7+0.67 
5 No Selection 
PENTOBARBITAL 2.5 20 6 100 2.0+1.48 
5 6 33 0 
10 6 0 0.9+0.8 
PHENOBARBITAL 2.5 45 5 100 0.7+0.42 
10 6 50 0 
40 6 0 0.7+0.42 
PROPRANOLOL 10 30 5 80 0 
R04-4602+DL-5- 25 1 h 
HYDROXYTRYPTOPHAN 100 30 4 100 0 
SALINE 15-60 14 100 0.5+0.37 
SCOPOLAMINE HYDRO-
BROMIDE 0.64 15 6 84 l.0+0.63 
1 No Selection 
TRIMETHADIONE 160 30 9 78 0.3+0.24 
320 6 67 2 •. 0j:.1 ~ 29 
2 No Selection ........ 
TABLE 5 continued 
Test Drug 
1% '!WEEN 80 + 
13% PROPYLENE 
GLYCOL 
VALPROIC ACID 
Dose 
(mg/kg) 
40 
160 
320 
640 
Pretreatment 
Time 
(Minutes) 
30 
45 
90 
4 Mean Responses 
( +s . E • ) on Non -
% Selecting Selected Lever 
N2 PTZ Lever3 Before Lever 
Selection 
10 
6 
8 
6 
100 
100 
75 
33 
3 No Selection 
0.3+0.29 
0 
0.4+0.26 
0.7+0.49 
1Following pretreatment with the test drug, the rats were injected with 
pentylenetetrazol (20 mg/kg). 15 min following the pentylenetetrazol 
injection, animals were placed in the.ir assigned Skinner box and allowed 
to make a lever selection. The lever with which ten responses were com-
pleted first was considered the selected lever. 
2 Number of rats tested. 
3 % of rats selecting the pentylenetetrazol lever. "No selection" indi-
cates that ten responses were not completed on either lever in the 10 
min session due to behavioral toxicity of the drugs. 
4 Responses (Mean~S.E.) emitted with nonselected lever before lever selec-
tion. Where N < 3 mean is given. 
TABLE 6. Antagonism Tests: Effect of Test Drugs on Response Rate in Rats Trained to Discriminate 
Between Pentylenetetrazol and Saline 
Responses/10 Min3 
Mean+S.E. % + S.E. 
4 
Pretrea trnent 
-· - -- -· --
Dose Time 
N2 
Test 
Test Drug (mg/kg) (Minutes) PTZ Saline Drug % PTZ % Saline 
ACEPERONE 0.64 30 4 895+72 1125+80 615+76 68+5 54+4 
- -
2.50 5 444+69 858+70 422+63 95+4 48+4 
- - - - -
AMITRYPTYLINE 10 30 6 410+72 853+80 213+75 51+13 24+6 
- - - -HYDROCHLORIDE 20 2 725 1325 70 10 6 
3 200+90 590+171 0 0 0 
- -
ATROPINE SULFATE 5 30 4 543+58 843+74 157+34 28+5 18+3 
- - - -1 290 960 0 0 0 
2 360 655 95 26 19 
CAFFEINE 20 30 5 385+117 668+170 543+120 163+25 85+18 
- - - -
-
CHLORDIAZEPOXIDE o. 64 30 10 660+56 809+61 703+45 111+7 90+6 
- - -
HYDROCHLORIDE 2.5 10 709+48 880+58 767+60 108+5 88+4 
10 10 807+95 951+90 776+58 100+7 84+7 
- - - -
-
CHLORPROMAZINE 1.25 30 4 443+94 620+21 258+31 68+18 45+16 
- - -5 4 638+105 1080+125 0 0 0 
-
CLO BA ZAM 2.5 30 6 885+82 1072+83 858+108 102+21 83+14 
10 6 872+100 1138+63 907+50 112+16 80+3 
40 5 728+116 853+94 540+134 88+36 64+14 
- - -
- -
\D 
...... 
TABLE 6 continued 
I 3 
Responses/10 Min 
Pretreatment Mean±..S .E. 
Dose Time 2 Test Test Drug (mg/kg) (Minutes) N PTZ Saline Dru9 
CLONAZEPAM 0.04 30 6 513+95 987+69 702+99 
- - -0.16 6 492+75 655+50 610+81 
0.64 6 457+73 700+106 595+80 
- - -
CLONIDINE 0.04 30 6 678+162 743+55 210+63 
-
HYDROCHLORIDE 0.16 5 782+48 1106+63 56+22 
- - -0.64 1 830 950 60 
3 663+157 1197+81 0 
-
DIAZEPAM 1.25 30 6 1002+47 1178+49 903+87 
-
2.5 6 743+48 757+67 820+62 
5 6 827+42 983+99 827+62 
- - -10 6 933+84 1073+66 588+154 
- - -
DIPHENYLHYDANTOIN 30 15 6 770+149 973+100 332+75 
60 6 690+90 865+148 267+101 
- - -
ETHANOL 250 15 3 553+60 907+38 500+110 
1000 4 630+172 893+49 300+46 
- - -2 595 1025 0 
ETHOSUXIMIDE 100 30 9 747+92 1001+111 643+91 
200 5 768+125 913+132 325+91 
- -2 560 675 0 
% + S.E. 4 
% PTZ % Saline 
145+19 73+11 
- -
128+13 91+9 
139+17 89+10 
- -
33+10 28+7 
7+3 5+2 
-7 6 
0 0 
91+8 76+7 
114+7 110+12 
101+8 90+13 
65+19 53+13 
-
52+12 33+7 
40+17 34+13 
-
93+25 56+14 
67+24 33+4 
- -
0 0 
84+4 64+7 
49+18 41+15 
- -0 0 
l.O 
"" 
TABLE 6 continued 
Responses/10 Min3 4 % + S.E. 
Pretreatment Mean + S.E. 
Dose Time 
N2 
Test 
Test Drug (mg/kg) (Minutes) PTZ Saline Drug % PTZ % Saline 
E'IOMIDATE 5 5 6 810+49 1087+50 793+77 99+9 73+6 
- - - - -SULFATE 10 1 380 990 310 82 31 
5 320+90 708+164 0 0 0 
10 2 h 4 595+115 870+310 125+55 20+5 14+7 
40 4 648+96 773+68 243+159 40+24 29+18 
- - - - -2 · 295 780 0 0 0 
FLUOXETINE 5 15 3 893+74 1240+29 730+15 83+5 59+1 
10 4 810+86 1128+54 370+97 44+9 32+7 
- - -
-
FLURAZEPAM 1.25 30 6 480+83 860+89 625+24 148+34 76+9 
- - -
DIHYDROCHLORIDE 5 6 963+74 1105+57 963+78 100+4 87+4 
20 6 1053+33 I 990+33 845+52 80+3 86+7 
- - - -
-
GAMMA-ACETYLENIC 100 2 h 5 1046+97 1116+59 195+125 22+13 18+10 
-
GABA 4 h 5 906+62 1048+83 214+112 22+10 23+13 
- - -1 890 1000 0 0 0 
8 h 4 1085+85 1203+110 610+206 61+23 57+22 
- - - -2 710 1180 0 0 0 
24 h 7 927+109 1110+101 400+91 46+15 38+12 
- - - - -4 1225 1125 0 0 0 
GAMMA-HYDROXY- 80 7 4 615+199 923+130 548+127 96+9 58+7 
BUTYRATE 160 4 538+160 660+155 328+94 75+18 47+5 
- -
-
320 4 810+390 775+275 0 0 0 
- -
l.D 
w 
TABLE 6 continued 
Responses/10 Min 3 4 
Mean+S.E. % + S.E. 
-
Pretrea tlnent 
Dose Time 
N2 
Test 
Test Drug (mg/kg) (Minutes) PTZ Saline Drug % PTZ % Saline 
GAMMA-VINYL 1000 4 h 4 658+112 975+106 0 0 0 
GABA 8 h 4 717+31 1102+39 0 0 0 
- -
24 h 1 730 670 260 36 39 
7 681+63 1091+27 0 0 0 
72 h 3 807+168 963+149 320+25 41+8 34+3 
- -1 350 1010 0 0 0 
HALOPERIOOL 0.16 45 6 975+86 1132+71 265+97 30+12 25+10 
-0.64 1 1120 1160 80 7 7 
MEPROBAMATE 5 30 6 733+125 1097+46 618+76 90+7 56+6 
- - - -20 6 803+45 1043+55 795+79 101+11 78+9 
80 6 798+112 1132"+47 872+59 122+21 78+4 
- - - - -
ME THY SERGI DE 2.5 30 5 508+83 606+76 366+62 74+10 62+11 
- - -
- -
IDRPHINE 10 15 3 676+102 980+98 223+74 36+14 24+10 
- -SULFATE 5 502+96 966+97 0 0 0 
- -
PENTOBARBITAL 2.5 20 6 901+44 1060+43 997+46 111+5 94+2 
- -5 6 813+98 822+135 837+97 103+6 107+9 
10 6 733+74 890+105 817+88 113+11 93+5 
- - - -
PHENOBARBITAL 2.5 30 6 784+142 988+81 708+137 92+6 70+11 
-
10 6 596+137 976+75 740+100 138+19 75+7 
10 6 778+94 966+63 632+91 81+4 65+5 
- - -
- -
ID 
.t. 
TABLE 6 continued 
Responses/10 Min 3 4 
Pretreatment Mean+S.E. % + S.E. 
Dose Time 
N2 
Te::;i: 
Test Drug (mg/kg) (Minutes) PTZ Saline Drug % PTZ % Saline 
PROPRANOLOL 10 30 5 668+97 1008+66 588+121 88+12 54+12 
- - - - -
R04-4602-DL-5-
HYDROXYTRYPTOPHAN 4 1 h t' , , , 
30 838+54 1233+73 330+68 39+6 27+5 
- - - -
SALINE -- 15-60 14 755+102 975+155 815+124 107+3 86+12 
- - - -
-
SCOPOLAMINE 0.64 15 6 906+67 1166+54 124+70 14+8 11+6 
-
-
HYDRO BROMIDE 1 900 1030 0 0 0 
TRIMETHADIONE 160 30 9 623+75 803+71 553+54 104+20 72+8 
320 6 602+74 783+110 305+76 46+9 37+7 
- - -
- -
2 685 900 0 0 0 
1% '!WEEN 80 
+ 13% PROPYLENE - 30 7 941+59 1243+30 941+81 103+10 75+6 
-
GLYCOL 
VALPROIC ACID 160 45 8 614+80 903+80 600+59 111+20 73+14 
320 6 885+53 1080+88 380+34 44+4 36+4 
- - - - -640 3 830+147 927+178 0+0 o+o o+o 
- -
1Test Drugs were administered intraperitoneally. Following pretreatment with the test drug the 
rats were placed in their assigned Skinner box and allowed to respond with the levers for 10 min. 
2 \0 Number of rats tested. V1 
TABLE 6 continued 
3Total responses (mean.2:._S.E.) emitted during the 10 min session following pretreatment with the 
test drug and during the preceding pentylenetetrazol (20 mg/kg) and saline session. 
4
values were obtained by dividing the total number of lever presses emitted following test 
drug pretreatment by the total number of respons.es during the preceding pentylenetetrazol 
(20 mg/kg) and saline session. 
l.O 
O' 
response rate during the PTZ and saline sessions preceding the 
test session. One rat did not make a lever selection after 
pretreatment with 5 mg/kg atropine. Two rats pretreated with 
10 mg/kg atropine selected the PTZ lever and these rats did 
not emit any responses with the saline lever before PTZ lever 
selection. Response rate during the 10 mg/kg atropine test 
session appeared to be decreased compared to the response 
rate during the PTZ and saline sessions preceding the test 
but the small number of animals prohibited statistical analy-
sis. 
Lack of Tolerance Development to Diazepam and Chlordiazepox-
ide in Antagonism of the PTZ Discriminative Stimulus (Table 7) 
Chronic administration of solvent, diazepam or CDP to 
rats tested acutely with these drugs for antagonism of the 
PTZ discriminative stimulus did not alter their ability to 
antagonize the discriminative stimulus produced by PTZ. All 
of the rats pretreated acutely with solvent for antagonism of 
the PTZ discriminative stimulus selected the PTZ lever after 
chronic solvent administration. Whereas 67 and 17% of the 
rats pretreated acutely for antagonism of the PTZ discrimina-
tive stimulus with 2.5 and 10 mg/kg diazepam selected the 
PTZ lever, 67 and 33% of these rats selected the PTZ lever 
after chronic diazepam administration. Similarly, whereas 
30 and 20% of the rats pretreated acutely for antagonism of 
the PTZ discriminative stimulus with 2.5 and 10 mg/kg CDP 
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selected the PTZ lever, 40 and 20% of these rats selected the 
PTZ lever after chronic CDP treatment. 
Tests for Diazepam and Haloperidol Antagonism of the Discrim-
inative Stimuli Produced by Cocaine, Yohimbine and R05-3663 
in Rats Trained to Discriminate Between Pentylenetetrazol 
(20 mg/kg) and saline (Tables 8 and 9). 
1. Cocaine 
As stated previously (Table 3) , 86% of the rats in-
jected with cocaine (20 mg/kg) selected the PTZ lever when 
tested for lever selection 15 min after the cocaine injec-
tion. Diazepam (5 mg/kg) produced a significant (Fisher 
Exact Probability, p<0.05) antagonism of the discriminative 
stimulus produced by cocaine as only 17% of the rats se-
lected the PTZ lever when cocaine (20 mg/kg) was preceded by 
a diazepam (5 mg/kg) injection. Prior to lever selection 
the rats emitted 2.3~1.43 responses with the nonselected 
lever. During the diazepam plus cocaine test session the 
rats emitted 223~93 responses. This was significantly less 
(Duncan's Multiple Range Test, p<0.05) than the 5532:_88 re-
sponses that were emitted by these rats during the PTZ ses-
sion preceding this test and the 658+87 responses that were 
emitted during the saline session preceding the test. 
Haloperidol (0.16 mg/kg) did not significantly (Fisher 
Exact Probability, p 0.05) antagonize the discriminative 
stimulus produced by cocaine. Wherea·s 86% of the rats se-
lected the PTZ lever after cocaine, 75% selected the PTZ 
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TABLE 7. Antagonism Tests with Diazepam and Chlordiazepoxide 
After Their Chronic Administration.l 
Drug 
SOLVENT 
Dose 
(mg/kg) 
DIAZEPAM 2.5 
10.0 
CHLORDIAZEPOXIDE 2.5 
10.0 
6 
6 
6 
10 
10 
% Selecting 
Acute 
100 
67 
17 
30 
20 ... 
PTZ Lever 3 
.. 
Cnronic 
100 
67 
33 
40 
20 
1 Rats were injected with the appropriate dose of either diazepam, chlor-
diazepoxide or solvent. 30 min later PTZ (20 mg/kg) was injected. 15 
min following the PTZ injection, animals were placed in their assigned 
Skinner box and allowed to make a lever selection. The lever with which 
ten responses were completed first was considered the selected lever. 
2 Nwnber of rats tested. 
3Percent of rats selecting PTZ lever. 
100 
lever when haloperidol was injected before cocaine. P.rior to 
lever selection the rats emitted 0."8±0.33 responses with the 
nonselected lever. Response rate during the haloperidol plus 
cocaine test session was significantly less (Duncan's Mul-
tiple Range Test, p<0.05) than response rate during the PTZ 
and saline session preceding the test. 
2. R05-3663 
R05-3663 (0.64-5 mg/kg) dose-dependently generalized 
to the discriminative stimulus produced by PTZ (Table 3) . Di-
azepam (5 mg/kg) pretreatment antagonized the discriminative 
stimulus produced by R05-3663 so that higher doses of this 
drug were required to produce PTZ lever selection. Whereas 
100% of the rats injected with 5 mg/kg R05-3663 selected the 
PTZ lever, none of the rats selected the PTZ lever when this 
dose of R05-3663 was preceded by a 5 mg/kg diazepam injection. 
However, 40 and 80% of the rats selected the PTZ lever when 
injected with 10 and 20 mg/kg R05-3663, respectively 30 min 
after diazepam (5 mg/kg) injection. Prior to lever selec-
tion these rats emitted 2.6±1.60, 0."8±0.80 and 0.6+0.60 
responses with the nonselected lever. Response rates during 
the diazepam plus R05-3663 (5 and 10 mg/kg) test session 
were not significantly different (Duncan's Multiple Range 
Test, p>0.05 and F.d. f.2,9=3.95, p>0.05) from response rates 
during the PTZ and saline sessions preceding these tests. 
However, response rate during the diazepam plus ROS-3663 
(20 mg/kg) test session was significantly less (Duncan's 
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Multiple Range Test, P<0.05) than response rate during the 
saline session but not the PTZ session preceding this test. 
3. Yohimbine 
Yohimbine (2.5 mg/kg) generalized to the PTZ discrim-
inative stimulus in six of twelve rats (Table 3). Diazepam 
(5 mg/kg) pretreatment antagonized the yohimbine discrimina-
tive stimulus in three out of four of these rats that se-
lected the PTZ leger after yohimbine alone. 
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TABLE 8. Tests for Diazepam and Haloperidol Antagonism of the Discrimina-
tive Stimuli Produced by Cocaine, Yohimnine and R05-3663 in 
Rats Trained to Discriminate Between Pentylenetetrazol (20 mg/kg) 
and Salinel 
Test Drug 
COCAINE 
DIAZEPAM 
DIAZEPAM 
+ 
COCAINE 
HALOPERIOOL 
HALOPERIDOL 
+ 
COCAINE 
YOHIMBINE 
DIAZEPAM 
+ 
YOHIMBINE 
R05-3663 
DIAZEPAM 
+ 
R05-3663 
Dose 
(mg/kg) 
20 
5 
5 
20 
0.16 
0.16 
20 
2.5 
5 
2.5 
5 
5 
5 
10 
20 
Pretreatment 
Time 
· (Minutesr 
15 
30 
45-90 
15-60 
75 
75 
15 
30 
60 
30 
30 
60 
30 
30 
30 
2 
N 
7 
6 
6 
5 
8 
4 
4 
6 
5 
5 
5 .. 
4 Mean Response s 
(+S.E.) on Non-
Selected Lever 
% Selecting Before Lever Se~ 
P~Z t~v~i 1~ctiori · 
86 1.7+1.2 
0 0 
17 
0 
75 
100 
25 
100 
0 
40 
80 
2. 3+1.43 
0.40+0.4 
0.75+ 
0 
1+1.0 
1. 2+0 .80 
2 .6+1.60 
0.8+0.80 
0.6+0.60 
1Following injection of the test drug the rats were placed in their 
assigned Skinner box and allowed to make a lever selection. The lever 
with which ten responses were completed first was considered the selected 
lever. 
2 Number of rats tested. 
3% of rats selecting the PTZ lever. 
4Responses (Mean±.S . E.) emitted with nonselected lever before lever 
selection. 
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TABLE 9. Response Rates During Tests for Diazepam and Haloperidol Antago-
nism of the Discriminative Stimuli Produced by Cocaine and 
R05-3663 in Rats Trained to Discriminate Between Pentylenetetra-
zol and Saline 
Respons~s/10 Hin 3 3 4 
Pretreatment Mean+S.E. 
Test1 Dose Time 2 Drug (m:J/kg) (Minutes) . ·N PTZ· Saline ·· 
COCAINE 20 15 7 843+38 991+74 
DIAZEPAM 5 45-90 
+ 
COCAINE 20 15-60 6 553+88 658+87 
HALOPERI-
DOL 0.16 75 
+ 
COCAINE 20 15 8 500+70 820+99 
R05-3663 5 30 6 396+64 587+140 
DIAZEPAM 5 60 
+ 
R05-3663 5 30 5 385+98 848+115 
10 30 5 605+103 850+94 
20 30 5 628+88 900+35 
1 Test drugs were administered intraperitoneally. 
the rats were placed in their assigned Skinner box 
spond with the levers for 10 min. 
2 
Number of rats tested. 
% S.E.+S.E. 
Test % % 
Drug PTZ· Saline 
767+77 93+12 82+13 
223+93 42+19 33+15 
315+55 83+24 40+8 
370+67 92+96 69+10 
563+35 206+87 70+10 
450+106 72+9 51+10 
303+162 50+23 23+17 
Following pretreatment 
and allowed to re-
3Total responses (Mean+S.E.) emitted during the 10 min session following 
pretreatment with the test drug and during the preceding pentylenetetra-
zol (20 mg/kg) and saline session. 
4
values were obtained by dividing the total number of responses emitted 
following test pretreatment by the total number of resonses during the 
precedi.ng pentylenetetrazol ( 20 mg/kg) and saline sessions. 
lOA 
DISCUSSION 
Acquisition of PTZ-Saline Discrimination 
A number of drugs are known to function as discriminative 
stimuli which reliably control operant behavior (for reviews 
see Schuster and Balster, 1977; Lal, 1977; Colpaert and Rose-
crans, 1978). Usually in these experiments laboratory ani-
mals are trained to emit one response when treated with a drug 
and an alternate response when treated with the drug vehicle, 
another dose of the same drug or a different drug. When ac-
quisition of such response differentiation is reliably estab-
lished, the drug is said to produce a discriminative stimulus 
which controls the differential response - emission in the 
trained subjects. 
The present experi~ent demonstrates that rats can learn 
to reliably discriminate between the effect of PTZ (20 mg/kg) 
and saline. A mean of 30 sessions was required for the rats 
to reach the discrimination criterion. A similar number of 
trials to reach a similar criterion was previously reported 
for many other psychoactive drugs (Weissman, 1978). As was 
the case with other drugs (Lal, 1976; 1977; Shearman et al., 
1978) the discriminative stimulus produced by PTZ was dose-
dependent. 
Previously PTZ was reported to produce state-dependent 
learning (Overton, 1966, 1973; Kurtz and Palfai, 1973). 
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Anxioqenic Property of PTZ as a Discriminative Stimulus 
1. Time Course of PTZ Discrimination 
In addition to its anxiogenic action, PTZ has also 
been reported to produce hallucinations in man (Rodin, 1958; 
Winter and Wallach, 1969). However, whereas the anxiogenic 
effect of PTZ diminishes soon after injection of PTZ is dis-
continued the hallucinations persist for up to 24 h after PTZ 
injection. In order to test the hypothesis that the discrim-
inative stimulus produced by PTZ in the rat was related to 
its anxiogenic action and not its hallucinatory effect, dis-
crimination of PTZ was tested at various times after injec-
tion of the drug. 
Pharmacokinetic studies of PTZ in rats show that 70-95% 
of this drug appears in the urine within 24 h (Rowles et al., 
1971; Vohland and Koransky, 1972). The cerebrospinal fluid 
and plasma half-life of a 20 mg/kg PTZ injection in cats has 
been reported to be approximately one hour (McMillen and 
Isaac, 1978). 
In the present study the discrimination of PTZ diminished 
as the reported tissue levels of this drug decreased. A sig-
nificant percentage of the rats no longer selected the PTZ 
lever when the reported blood levels of PTZ were significant-
ly decreased. These data support the hypothesis that the dis-
criminative stimulus produced in the rat is related to its 
anxiogenic property and not its hallucinatory effect. 
106 
2. Generalization Tests with Other Anxiogenics 
To test the hypothesis that the discriminative stim-
ulus produced by PTZ in the rat was related to its anxiogenic 
action in man (Rodin, 1958; Rodin and Calhoun, 1970; Winter 
and Wallach, 1969), other anxiogenic stimulants were tested 
for generalization to the PTZ discriminative stimulus. 
Cocaine has been well recognized to induce anxiety in man 
(Cohen, 1975; Siegel, 1977; Wesson and Smith, 1977). Dose-
dependent generalization by cocaine to the PTZ discriminative 
stimulus supports the hypothesis that the discriminative stim-
ulus property of PTZ in the rat is related to its anxiogenic 
action in man. Additional support for this was provided by 
the finding that the anxiolytic drug, diazepam, antagonized 
the cocaine discriminative stimulus. Whereas the nonanxiolyt-
ic drug, haloperidol, did not antagonize the cocaine dis-
criminative stimulus. 
In addition to its anxiogenic action, however, cocaine 
is also a psychomotor stimulant. In order to determine that 
psychomotor stimulation was not the basis of the cocaine gen-
eralization to PTZ, nonanxiogenic psychomotor stimulants were 
tested for generalization to PTZ. Neither d-amphetamine, 
methylphenidate nor caffeine generalized to the PTZ discrim-
inative stimulus suggesting that the psychomotor stimulant 
property of cocaine was not the basis of its discrimination 
to PTZ. 
Several investigators (Holmberg and Gershon, 1961; Ingram, 
1962; Gershon and Lang, 1962; Garfield et al., 1967) have 
107 
reported the anxiety-like effects produced by yohimbine in 
man . Amobarbital was reported to reduce the anxiety response 
to yoh~mbine while imipramine and epinephrine potentiated 
this effect (Holmberg and Gershon, 1961). 
In the present study, yohimbine partially generalized to 
the discriminative stimulus property of PTZ. Furthermore, di-
azepam antagonized the yohimbine discriminative stimulus in 
those rats that perceived the yohimbine stimulus as similar 
to the PTZ discriminative stimulus. These data support the 
hypothesis that the discriminative stimulus property of PTZ 
in the rat is related to its anxiogenic action in man . 
ROS-3663 (l,3-dihydro-5-methyl-2H-l,4 benzodiazepin-2-one) 
is structurally related to the anxiolytic drug, diazepan 
(Schlosser and Franco, 1979). However, unlike diazepam, 
ROS-3663 does not bind to benzodiazepine receptors (Speth et 
al., 1979); O'Brien and Spirt, 1980) and antagonizes the ef-
fect of diazepam (Schlosser and Franco, 1979). Because the 
action of ROS-3663 is opposite to that of anxiolytic benzo-
diazepines this compound might be expected to be anxiogenic. 
Recently, O'Brien and Spirt (1980) speculated that if 
the anxiolytic action of benzodiazepines were considered to 
be mediated through an antagonistic action then a molecule 
structurally similar to ROS-3663 could exist in brain to 
function as an endogenous anxiety producing li~and. In the 
present study, ROS-3663 dose-dependently generalized to the 
PTZ discriminative stimulus. Furthermore, the discriminative 
stimulus strength of ROS-3663 was attenuated by diazepam. 
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These data provide behavioral evidence that ROS-3663 may 
structurally resemble a naturally occurring anxiety-inducing 
ligand · and support the hypothesis that the discriminative 
stimulus produced by PTZ in the rat is related to the anxio-
genic action in man. 
It has been reported that patients poisoned with strych-
nine are extremely apprehensive and fearful of impending 
death (Polson and Tattersall, 1969; Franz, 1975). Strychnine 
generalization to the discriminative stimulus produced by PTZ 
supports the hypothesis that the discriminative stimulus 
property of PTZ in the rat is related to its anxiolytic ac-
tion in man. 
In addition to the anxiogenic action of strychnine and 
ROS-3663, however, these drugs are also convulsants. In or-
der to determine that the convulsant action of strychnine 
and ROS-3663 was not the basis of their generalization to 
the PTZ discriminative stimulus several nonaxiogenic convul-
sant drugs were tested for generalization to the PTZ discrim-
inative stimulus. 
Bemegride, a central nervous system stimulant and con-
vulsant drug like PTZ (Hahn, 1960) dose-dependently general-
ized to the PTZ discriminative stimulus. This would suggest 
that the convulsant action of strychnine and ROS-3663 was the 
basis of their generalization to the PTZ discriminative stim-
ulus and that the discriminative stimulus produced by PTZ was 
related to its own convulsant action. However, none of the 
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other convulsant druqs tested, including picrotoxin, bicucul-
line, 3-mercaptoproprionic acid and nicotine, generalized to 
the PTZ discriminative stimulus. 
Also, gamma-hydroxybutyrate that produces a hypersynchro-
nous EEG in the chick (Osuide, 1972), rat (Marcus et al., 
1967; Godschalk et al., 1976, 1977), cat (Winters and Spooner 
1965), rabbit and man (Schneider et al., 1963), that is selec-
tively antagonized by anti-petit rnal drugs (Godschalk et al., 
1976) and has been compared to petit mal epilepsy (Winters 
and Spooner, 1965; Snead et al., 1976; Godschalk et al., 1977), 
did not generalize to the PTZ discriminative stimulus. These 
data suggest that the convulsant action of strychnine and 
R05-3663 was probably not the basis of their generalization 
to the PTZ discriminative stimulus and that a subconvulsant 
or petit mal like brain state likely to be produced by these 
drugs was not the basis of the discriminative stimulus pro-
duced by PTZ. The finding that bemegride generalized to the 
PTZ discriminative stimulus suggests that this drug may be 
anxiogenic. 
3. Blockade of the PTZ Discriminative Stimulus by Anxio-
lytics 
As another approach to test the hypothesis that the 
discriminative stimulus produced by PTZ in the rat was re-
lated to its anxiogenic action in man, antagonism of the PTZ 
discriminative stimulus by clinically effective anxiolytic 
drugs was tested. 
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Several benzodiazepine anxiolytics, barbiturate type an-
xiolytics as well as a propanediol carbamate anxiolytic ef-
fectively antagonized the PTZ discriminative stimulus in a 
dose-dependent manner and in nonsedative doses. In addition, 
valproic acid, which was recently found to have anxiolytic 
properties in a conflict test (Lal et al., 1979) also dose-
dependently antagonized the PTZ discriminative stimulus. 
These data support the hypothesis that the discriminative 
stimulus produced by PTZ in the rat is related to its anxio-
genic action in man. 
The potency of the various drugs effective in antagoniz-
ing the PTZ discriminative stimulus was highly correlated 
with their effective doses in a widely accepted conflict test 
used to measure anxiolytic activity (Figure 3) as well as 
their clinically effective doses (Figure 4). These data also 
support the hypothesis that the discriminative stimulus 
property of PTZ in the rat was related to its anxiogenic ac-
tion in man. 
In addition to anxiolytic activity, however, all of the 
drugs that antagonized the PTZ discriminative stimulus are 
also central nervous system depressants. Several investi-
gators (Warner, 1965; Goldberg et al., 1967; Margules and 
Stein, 1969; Stein et al., 1975; Cook and Sepinwall, 1975) 
have reported that tolerance develops only to the depressant 
action benzodiazepines. Therefore, lack of tolerance develop-
ment to other actions of these drugs in experimental animals 
Figure 3. Correlation between the effective dose of anxio-
lytic drugs in antagonnzing the anxiogenic qis-
criminati ve st.irrulus of PTZ and their effective 
doses in the ronflict test. 
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has often been employed as a tool to identify pharmacological 
actions for their predictive value for clinical efficacy 
(Fielding and Lal, 1979; Lippa et al., 1979). Because benzo-
diazepines have been the most widely studied anxiolytic drugs 
with respect to tolerance development to their anxiolytic ac-
tions, it was investigated whether tolerance would not de-
velop to two prototype benzodiazepines, chlordiazepoxide and 
diazepam, in antagonism of the PTZ discriminative stimulus. 
It was hypothesized that if the antagonistic property of these 
benzodiazepines in the PTZ discrimination paradigm was related 
to their anxiolytic action tolerance would not develop. Pre-
viously, lack of tolerance development to the prevention of 
PTZ-induced convulsions by diazepam was reported (Fuxe et al., 
1975; Juhasz and Dairman, 1977; Lippa and Regan, 1977). 
The ability of either diazepam or chlordiazepoxide to an-
tagonize the PTZ discriminative stimulus was not affected by 
their chronic administration even though this treatment was 
more than sufficient (Cook and Sepinwall, 1975; Goldberg 
et al., 1967; Margules and Stein, 1968; Stein et al., 1975) 
to produce tolerance to the depressant action of these drugs. 
The present data are consistent with previous findings (Fuxe 
et al., 1975; Jahasz and Dairman, 1977; Lippa and Regan, 
1977) that show lack of tolerance development to prevention 
of PTZ induced convulsions by diazepam. Because tolerance 
develops to the depressant but not anxiolytic action of benzo-
diazepines these data support the hypothesis that antagonism 
of the PTZ discriminative stimulus by these drugs is related 
to their anxiolytic action. 
A~ditional data which supports the suggestion that an-
tagonism of the PTZ discriminative stimulus was related to 
anxiolytic action and not to the central nervous system de-
pressant activity of these drugs was provided through antago-
nism tests with nonanxiolytic central nervous system depres-
sants. Etomidate is a nonbarbiturate hypnotic which is used 
for the induction of anesthesia because of its short duration 
of action (Jannsen et al., 1975). The anxiolytic action of 
etomidate has not been reported to date. Although ethanol is 
widely considered an anxiolytic, the anti-anxiety effect of 
this drug has not been clearly demonstrated (Sepinwall and 
Cook, 1978) • Whereas morphine is known to alleviate anxiety 
during opiate withdrawal (Redmond, 1979) it does not relieve 
anxiety in opiate free individuals. Chlorpromazine and hal-
operidol, useful in the treatment of psychoses, do not de-
crease anxiety (Rickels et al., 1979). 
None of these central nervous system depressants were 
effective in antagonizing the discriminative stimulus pro-
duced by PTZ. These data indicate that drugs that depress 
the central nervous system but do not possess anxiolytic ac-
tivity do not antagonize the PTZ discriminative stimulus. 
Therefore these data support the hypothesis that the dis-
criminative stimulus produced by PTZ in the rat is related 
to its anxiogenic action. 
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In addition to their anxiolytic and depressant actions, 
all of the drugs that were effective in antagonizing the PTZ 
discriminative stimulus are also effective against PTZ con-
vulsions (Childress and Gluckman, 1964; Banziger, 1965; 
Swingard and Castellion, 1966; Ludwig and Potterfield, 1971; 
Dren et al., 1978; Lippa et al., 1979). Based upon these 
data, the finding that tolerance does not develop to diazepam 
in antagonizing PTZ convulsions (Lippa and Regan, 1977) as 
well as other considerations (Lippa et al., 1979), it has 
been suggested that the ability of drugs to prevent or antag-
onize or prevent PTZ convulsions may reflect their anxiolytic 
property (Hill and Tedeschi, 1971; Lippa and Regan, 1977; 
Lippa et al., 1979). 
Therefore, to test the hypothesis that antagonism of the 
PTZ discriminative stimulus by these drugs was not related to 
their anticonvulsant action, antagonism of the PTZ discrimi-
native stimulus with anticonvulsants that lack clinical anxi-
olytic actions was tested. 
Trimethadione and ethosuxirnide are known to protect lab-
oratory animals against PTZ produced convulsions (Everett and 
Richards, 1944; Toman and Goodman, 1948, Swinyard and 
Castellion, 1966; Woodbury and Fingl, 1975). These drugs are 
effective in the treatment of petit-mal epilepsy (Woodbury 
and Fingl, 1975) but not in the treatment of anxiety. In the 
present experiment neither trimethadione nor ethosuximide an-
tagonized the discriminative stimulus produced by PTZ. 
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Etomidate like trimethadione and ethosuximide, is known 
to protect mice and rats against the convulsant action of PTZ 
(Desmedt et al., 1976). However, etomidate also did not an-
tagonize the PTZ discriminative stimulus. 
Unlike trimethadione, ethosuximide and etomidate, di-
phenylhydantoin is an anticonvulsant which is ineffective in 
petit mal epilepsy (Woodbury and Fingl, 1975) and does not 
protect against pentylenetetrazol-induced convulsions (Everett 
and Richards, 1944; Toman and Goodman, 1948; Swinyard and 
Castellion, 1966) • Diphenylhydantoin did not block the dis-
criminative stimulus produced by pentylenetetrazol. 
There is a high correlation (R=0.95; p < 0.05) between the 
potency of drugs effective in antagonizing the PTZ discrimi-
native stimulus and their effective doses against PTZ-induced 
convulsions (Figure 5). However, whereas all drugs that an-
tagonize the PTZ discriminative stimulus prevent PTZ convul-
sions not all drugs that are effective against PTZ convul-
sions antagonize the PTZ discriminative stimulus. These data 
suggest that the anticonvulsant action of the drugs effec-
tive in antagonizing the PTZ discriminative stimulus is not 
the property that is responsible for this effect. These data 
also suggest that the mechanism of action of the PTZ in pro-
ducing convulsions is different from that underlying its mech-
anism for producing a discriminative stimulus. Furthermore 
these data suggest that antagonism of the PTZ discriminative 
stimulus is a better measure of anxiolytic activity than is 
antagonism of PTZ seizures. 
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Neurochemical Correlates of the Anxioaenic Discriminative 
Stimulus Property of PTZ 
l i8 
The exact neurochemical basis for anxiety is unknown. 
However, it is possible that some indication of this may be 
obtained from the postulated mechanism of action of anxio-
lytic drugs with the assumption that the neurochemical basis 
for anxiety is opposite to that for the anti-anxiety action 
of anxiolytic drugs. 
Benzodiazepines are the most effective and thus most 
widely prescribed drugs for the treatment of anxiety (Howard 
and Pollard, 1977). Also, this class of anxi9lytics has been 
the most extensively studied with respect to their mechanism 
of action (Costa and Greengard, 1975; Sepinwall and Cook, 
1978; Koe, 1979). 
In the present study, it was hypothesized that the neuro-
chemical basis of the anxiogenic discriminative stimulus pro-
perty of PTZ was opposite to that of the postulated neuro-
chemical mechanism(s) responsible for the anxiolytic action 
of benzodiazepines. To test this hypothesis, drugs known to 
have effects opposite to those of benzodiazepines on the neu-
rotransmitter systems postulated to mediate the anxiolytic 
action of benzodiazepines and drugs known to have a similar 
effect as benzodiazepines on these neurotransmitter systems 
were tested for generalization to and antagonism of the anxi-
ogenic discriminative stimulus property of PTZ. 
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1. Garruna-aminobutyric Acid (GABA) 
A functionally significant interaction between benzo-
diazep~nes and brain gamma-aminobutyric acid (GABA) became 
apparent from a variety of neurochemical (for reviews see 
Costa et al., 1978, Costa and Guidotti, 1979) and neurophysio-
logical (for review see Haefly, 1978) experiments. However, 
the pharmacological significance of such an inteiaction is 
unclear. Whereas the anticonvulsant, sedative, and muscle 
relaxant actions of benzodiazepines seem to be related to GABA-
ergic mechanisms (Cook and Sepinwall, 1975; Lippa- et al., 
1979), a similar relationship for the anxiolytic action of 
benzodiazepines is not clear. 
To measure anxiolytic actions of drugs in experimental 
animals, one test that is considered quite specific is the 
conflict paradigm where reduction of response suppression by 
"confliotful" stimuli is measured (Lippa' et al., 1979, Sepin-
wall and Cook, 1978) . Inthis test, benzodiazepines are 
known to show high potency and efficacy in nonsedative doses. 
Therefore, the conflict model has been used to evaluate vari-
ous neurochemical hypothesis for anxiolytic activity. Cook 
and Sepinwall (1975) reported that the GABA-T inhibitor, amino-
oxyacetic acid (AOAA), was without anti-conflict activity 
alone and did not potentiate the anticonflict effect of diaze-
pam. Tye et al. (19_79) also reported that AOAA lacked anti-
conflict effect. These data might suggest that alteration of 
brain GABA is not related to anti-anxiety action. However, 
i-20 
recent studies of Iadrola and Gale (1979,a,b) show that the 
neuroanatomical sites of action of this GABA-T inhibitor is 
not appropriate for anxiolytic activity. First of all this 
drug elevates brain GABA outside of nerve terminals. In-
creasing the concentrations of GABA at these sites may actual-
ly inhibit neuronal GABA release because of its action on pre-
synaptic autoreceptors. In addition, the elevation of GABA 
by AOAA is more pronounced in extrapyramidal areas. The 
GABA-T inhibitor, valproic acid, on the other hand, increases 
brain GABA levels predominantly within nerve terminals and 
in brai~ sites in the limbic areas (Iadrola and Gale, 1979a,b). 
Therefore, the lack of anxiolytic action by some GABA-T in-
hibitors may be due to the inappropriate site of their action. 
Valproic acid's efficacy as an anxiolytic drug may be due to 
an action at more appropriate sites. 
Sullivan et al. (1978) and Cook and Sepinwall (1979) 
systemically administered the GABA receptor agonists musci-
mol and 4,5,6,7-tetrahydroisoxazolo (5, 4-c) pyridin-3-ol 
(THIP) to examine their effect on conflict behavior. Where-
as muscimol was weakly active, THIP was inactive. Neither 
muscimol nor THIP potentiated the anticonflict effect of 
benzodiazepines in this test. However, several investigators 
(Baraldi et al., 1979; Maggi and Enna, 1979; Enna et al., 
1979) have reported that muscimol does not penetrate into 
the brain after systemic administration. This evidence may 
explain the lack of anticonflict activity of muscimol and 
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and its structural analogue, THIP. Recently, Guidotti (per-
sonal communication) injected muscimol and THIP intraventricu~ 
larly and reported that both of these drugs produced anti-
conflict activity in rats~ 
Earlier data which suggested that the anticonflict ac-
tivity of benzodiazepines might be -mediated oy GABA were pro-
vided by Stein et al. ll975) and Zakusov et· al. (1977). These 
investigators reported that the anti~conflict activity of 
benzodiazepines was reduced by the GABA antagonists picro-
toxin, bicuculline or thiosemicarbizide. 
Therefore, using the conflict model much data has been 
generated to suggest that th.e anxiolytic action of benzodiaze..-
pines may be mediated by enhancing GABA activity. It may be 
hypothesized then, that anxiety is due to a deficit in GABA 
neuronal function. 
In order to test the hypothesis that decreased GABA neu-
ronal activity was the neurochemical basis for the anxiogenic 
discriminative stimulus property of PTZ, generalization to 
the PTZ discriminative stimulus with GABA antagonistic drugs 
and antagonism of the PTZ discriminative stimulus with GABA 
minetic drugs was tested. 
Picrotoxin and bicuculline were used as antagonists of 
tne postsynaptic inh1Bitory action of GABA (Curtis and 
Johnson, 1974). Whereas bicuculline acts at the receptor 
sites (Curtis and Johnson, 1974) , picrotoxin seems to act at 
chloride channels (Olsen· et ·a1., 1978a,b). Schecter and 
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Tranier (1977) found that GABA-transaminase inhibitors pro-
long the onset of seizure and death following picrctoxin but 
not following bicucuclline. Other differences between picro-
toxin and bicuculline have been reported with respect to 
GABA-receptor sensitivity (Krnjevic, 1974), blockade of GABA 
binding to brain receptors (Zukin et al., 1974), stimulation 
of [ 3H]-GABA release from brain tissue (Collins, 1973; John-
ston and Mitchell, 1971), alteration of specific r3H]-diaze-
pam binding ih cortical membranes (Tallman et al., 1978) and 
. --
induction of epileptic spikes following topical application 
and systemic injection (Edmonds and Bellin, 1976) . 
Whereas, picrotoxin partially generalized to the PTZ 
discriminative stimulus, bicucuclline did not generalize. 
Therefore, these data do not conclusively support the hypo-
thesis that the anxiogenic discriminative stimulus property 
of PTZ is related to decreased GABA neuronal activity. 
3-Mercaptopropionic acid is a convulsant drug that acts 
by inhibiting glutamate decarboxylase and producing a sub-
sequent decrease in the concentration of brain GABA (Lamar, 
1970). Like picrotoxin, 3-mercaptopropionic acid partially 
generalized to the PTZ discriminative stimulus. Therefore 
these data although suggestive do not fully support the hy-
pothesis that decreased GABA function is the basis of the 
anxiogenic discriminative stimulus property of PTZ. 
R0-3663 is a convulsant benzodiazepine that selectively 
antagonizes the effect of GABA at spinal and peripheral neu-
ronal sites (Schlosser and Franco, 1979). In addition, this 
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drug has been reix>rted to inhibit the GABA enhancement of 
3H-diazepam binding (O'Brien and Spirt, 1980) and binding of 
the GABA receptor antagonist, alpha picrotoxiu in Leeb-
Lundberg et al. (1979). ROS-3663 dose-dependently general-
ized to the PTZ discriminative stimulus. Furthermore, the 
discriminative stimulus strength of ROS-3663 was attenuated 
by diazepam. Although the exact neurochemical basis through 
which ROS-3663 produces its discriminative stimulus cannot be 
determined at present, these data support the hypothesis that 
decreased GABA neuronal activity is the neurochemical basis 
of the PTZ discriminative stimulus. 
Based upon the differential antagonism of iontophoreti-
cally applied etomidate and GABA by bicuculline but not by 
strychnine, Evans and Hill (1978) proposed etomidate to be a 
central GABA-mimetic drug. Etomidate did not antagonize the 
PTZ discriminative stimulus. The inability of etomidate to 
antagonize the PTZ discriminative stimulus does not support 
the hypothesis that discriminative stimulus is related to a 
deficit in brain GABA function. It should also be noted, 
however, that whereas etomidate was ineffective in blocking 
the PTZ discriminative stimulus, other sedative hypnotics 
such as pentobarbital and phenobarbital which also possess 
anxiolytic activity were effective antagonists of the pen-
tylenetetrazol discriminative stimulus. 
At higher dose levels, ganuna-hydroxybutyrate acts like 
a GABA agonist in the central nervous system (Anden and 
Stock, 1973; Roth and Nowycky, 1977). Pretreatment of the 
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animals with gaITlll1a-hydroxybutyrate did not antagonize the 
discriminative stimulus produced by PTZ also suggesting that 
the PT~ discriminative stimulus is not related to decreased 
GABA neuronal activity. 
Gamma-acetylentic GABA (GAG) and gamma-vinyl-GABA (GAG) 
are inhibitors of GABA-T which increase the brain GABA levels 
of mice and rats (Jung et al., 1977a; Jung et al., 1977b) and 
protect animals against seizures induced by audiogenic stimu-
lation, strychnine, isoniazid, thiosemicarbizide and electric 
shock (Schecter et al., 1977a,b), but not picrotoxin, bicu-
culline nor PTZ (Schecter et al., 1977a,b) antagonized the 
discriminative stimulus produced by PTZ. Thus these data do 
not support the hypothesis that the PTZ discriminative stimu-
lus is related to a deficit of brain GABAergic functioning. 
However, it may be premature to consider the above data 
as going against the hypothesis that the anxiogenic discrim-
inative stimulus property of PTZ is related to decreased GABA 
neuronal activity. Recently, Iadrola and Gale (1979a,b) have 
shown that the GABA-T inhibitors GAG and GVG increase brain 
GABA primarily in nonsynaptosomal sites such as glia. 
In order to overcome these shortcomings the indirectly 
acting GABA mimetic drug, valproic acid, was tested for an-
tagonism of the PTZ discriminative stimulus. Although val-
proic acid inhibits GABA-T (Godin et al., 1969, Simler et al . , 
1973; Fowler et al., 1975), enzyme-kinetic studies show that 
it increases brain GABA levels primarily by causins an accu-
mulation of succinic semialdehyde through inhibition of 
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succinic semialdehyde dehydrogenase (Van der Lann et al., 
1979). The succinic semialdehyde in turn blocks the conver-
sion of GABA to succinic semialdehyde through product inhi-
bition. These actions are preferentially localized within 
the nerve terminal (Van der Lann et al., 1979; Bruinvels 
~_!;:al., 1979). In addition, whereas other GABA-T inhibitors 
ca.use GABA elevation primarily in the compartments outside of 
nerve terminals, GABA elevation produced by valproic acid is 
primarily located ih nerve terminals (Iadrola and Gale, 1979; 
Sarhan and Seilar, 1979). Valproic acid has also been re-
ported to inhibit the reuptake of GABA into nerve terminals 
{ftarvey, 1976). Valproic acid dose-dependently antagonized 
the anxiogenic discriminative stimulus produced by PTZ. These 
data support the hypothesis that a deficit in GABA neuronal 
activity is the neurochemical basis of the anxiogenic dis-
criminative stimulus property of PTZ. These data also sug-
gest that valproic acid may be a clinically effective anxio-
lytic drug and that deficits i.n GABA functioning are im-
portant for anxiety. Furthermore these data suggest that 
antagonism of the PTZ discriminative stimulus by benzodiaze-
pines, and thus their anxiolytic action might be related to 
thei.r property of enhancing GABA transmission. 
2. Glycine 
A significant correlation between the ability of a 
series of J5enzodiazepines to reduce 3H-strychnine binding 
to glycine receptors and their clinical effects led to the 
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proposal that these drugs might produce their muscle relax-
ant and anti-anxiety action by mimicking glycine at its re-
ceptor ~ites (Young et al., 1974; Snyder and Enna, 1975). 
However, when Cook and Sepinwall (1975), using the data of 
Young et al. (1974), compared the 3H-strychnine displacement 
potency of ten benzodiazepines with their anticonflict paten-
cy, they did not £ind a significant correlation. Because 
there was a significant correlation between anticonflict po-
tency and potency in a human bioassay it was concluded that 
the affinity of benzodiazepines £or the glycine receptor was 
not correlated with anxiolytic activity. Furthermore, Stein 
et al. (1975) reported that although strychnine reduced the 
anticon£lict effect of oxazepam it also depressed unpunished 
responding suggesting that this effect was nonselective. 
In order to test the hypothesis that decreased glyciner-
gic activity was the neurochemical basis of the anxiogenic 
discriminative stimulus property of PTZ, the glycine antago-
nist (Curtis and Johnson, 1974) strychnine, was tested for 
generalization to the PTZ discriminative stimulus. 
Although not completely strychnine generalized to the 
PTZ discriminative stimulus thus supporting the hypothesis 
that decreased glycinergic activity was the basis £or the 
anxiogenic discriminative stimulus property of PTZ. 
McDonald and Barker (1977) reported that whereas PTZ 
antagonized the post-synaptic inhibitory responses to GABA 
in a mammalian tissue culture system it did not affect gly-
cine responses. Therefore, unless it is de:rronstrated that 
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PTZ antagonizes glycine the hypothesis that the neurochemical 
basis of the PTZ discriminative stimulus is due to decreased 
glycin~rgic activity might not be tenable. There was consid-
erable evidence presented earlier that suggests that ·the dis-
criminative stimulus produced by PTZ was related to decreased 
GABA Neuronal activity. Because both GABA and glycine are 
inhibitory neurotransmitters it may be suggested that inter-
ference with either of these inhibitory systems produces a 
discriminative stimulus that provides the basis for the com-
mon discriminative stimulus properties of these drugs. 
3. Phosphodiesterase Inhibition 
Based upon a significant correlation between the in 
vitro potency of several drugs in inhibiting phosphodiester-
ase and their potency in the thirsty rat conflict test, Beer 
et al. (1972) proposed that the anxiolytic activity of drugs 
may be related to their ability to inhibit this enzyme. In 
support of this hypothesis, Weinryb et al. (1975), found that 
a series of substituted pyrazoF--(3, 4b) -pyr idines that were 
potent inhibitors of phosphodiesterase had significant anti-
conflict activity. However, Morrison (1969) and Cook and 
Sepinwall (1975) did not find significant anticonflict ef-
feet of phosphodiesterase inhibitors in a lever press con-
flict test. Furthermore, Collins et al. (1976) reported 
that the potent phosphodiesterase inhibitor, SQ 65,396 was 
without anxiolytic effect compared to diazepam and placebo 
in psychoneurotic patients. 
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In order to test the hypothesis that the ability of ben-
zodiazepines to antagonize the discriminative stimulus pro-
perty pf PTZ was not related to their ability to inhibit 
phosphodiesterase, antagonism of the PTZ discriminative stim-
ulus with the phosphodiesterase inhibitor, caffeine, was 
tested. 
Caffeine did not antagonize the anxiogenic discriminative 
stimulus property of PTZ. This finding supports the hypothe-
sis that the ability of benzodiazepines to antagonize the PTZ 
discriminative stimulus was not related to their ability to 
inhibit phosphodiesterase. These data also support previous 
work (Morrison 1969; Cook and Sepinwall, 1975; Collins et al., 
1976) that suggests that the anxiolytic action of benzodiaze-
pines is not related to their inhibition of phosphodiesterase. 
4. Acetylcholine 
There is no clear correlation between the effect of 
benzodiazepines on cholinergic function and their anti-
anxiety action. Benzodiazepines were reported to increase 
rat brain acetylcholine levels (Consolo et al., 1975). The 
functional significance of this, however, is unclear as there 
was no correlation between the muscle relaxant or anti-PTZ 
of the benzodiazepines and their effect on acetylcholine even 
though PTZ has been reported to cause a decrease in rat brain 
acetylcholine (Giarrnan and Pepeu, 1962; Beani et al . , 1969; 
Longoni et al., 1974; Consolo et al., 1975) by causing a mas-
sive release of this neurotransmitter. In one behavioral 
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study, Soubrie et al. (1976) reported that diazepam antago-
nized the hyperactivity elicited by anticholinergics in mice. 
This effect was blocked by picrotoxin implicating the in-
volvement of GABA mechanism for this action of diazepam. 
In donflict tests, cholinergic agonists (Morrison, 1969) 
or antagonists (Hanson et al., 1970; Miczek, 1973) were with-
out significant anticonflict effect. In order to test the 
hypothesis that the anxiogenic discriminative stimulus pro-
perty of PTZ was related to its effect on cholinergic func-
tion, generalization to and antagonism of the PTZ discrimi-
native stimulus with cholinergic agonistic and antagonists 
was tested. 
None of the cholinergic drugs tested either generalized 
to or antagonized the PTZ discriminative stimulus. These 
data do not support the hypothesis that the neurochemical 
basis of the anxiogenic discriminative stimulus property of 
PTZ was related to its action on cholinergic function. Fur-
thermore , these data suggest that the ability of benzodiaze-
pines to antagonize the PTZ discriminative stimulus was not 
related to their affect on cholinergic function. 
5. Serotonin 
There is considerable biochemical (Stein et al . , 
1975) and behavioral (for reviews see Sepinwall and Cook, 
1978; Koe, 1979) evidence obtained from animal experiments 
that the benzodiazepines may exert their anti-anxiety action 
by decreasing serotonin activity . 
130 
Stein et al. (1975) reported that whereas tolerance de-
veloped to the depressant action and effect of benzodiaze-
pines on decreasing norepinephrine turnover, tolerance did 
not develop to their anticonflict effect or their effect of 
decreasing serotonin turnover. Using conflict paradigms it 
has been demonstrated that reduction serotonin activity by 
inhibition serotonin synthesis (Robichaud and Sledge, 1969; 
Geller and Blum, 1970; Schoenfeld, 1976), blockade of sero-
tonin receptors (Graef£ and Schoenfeld, 1970; Graeff, 1974; 
Stein et al., 1973; Winter, 1972) or destruction of serotonin 
nerve terminals (Stein et al., 1975) produces significant 
anticonflict effects. However, there have been some reports 
(Winter, 1972; Blakely and Parker, 1973; Cook and Sepinwall, 
1975a) that show a lack of anticonflict effect of serotonin 
antagonistic drugs. Whereas serotonin antagonists are usual-
ly reported to have anticonflict effects, serotonin agonists 
have been reported (Graeff and Schoenfeld, 1970; Winter, 
1972; Geller et al., 1974) to significantly suppress conflict 
behavior. 
In order to test the hypothesis that the anxioqenic dis-
criminative stimulus property of PTZ was related to an ago-
nistic effect of this drug on serotonin function, generaliza-
tion to the PTZ discriminative stimulus with serotonin ago-
nists and antagonism of the PTZ discriminative stimulus with 
serotonin antagonists was tested. 
Neither of the serotonin agonists used in this study 
(5-HTP and fluoxetine) generalized to the PTZ discriminate 
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stimulus. Furthermore, the serotonin receptor antagonist, 
methysergide, did not antagonize the discriminative stimulus 
proper~y of PTZ. These data do not support the hypothesis 
that the neurochemical basis of the anxiogenic discriminative 
stimulus property of PTZ was related to an agonistic effect 
on serotonin function. Furthermore, these data suggest that 
the ability of benzodiazepines to antagonize the PTZ discrim-
inative stimulus is not related to their ability to decrease 
serotonin transmission. 
It is interesting that serotonin antagonists are not 
clinically effective anxiolytics therefore reduction of sero-
tonin function by these drugs might not be the neurochemical 
basis for their anxiolytic action as suggested by other ani-
mal studies. 
6. Catecholamines 
Benzodiazepines are known to decrease the turnover 
of both norepinephrine and dopamine (for review see Koe, 
1979). There is no clear evidence, however, that this effect 
is related to the anxiolytic activity of these drugs. Fuxe 
et al. (1975) reported that diazepam antagonized increases 
in norepinephrine turnover produced by stress or injection of 
the anxiogenic drug yohirnbine. Gray (1976) reported similar 
effects for chlordiazepoxide as well as norepinephrine syn-
thesis inhibitors or lesions of the dorsal noradrenergic 
bundle against stress. Lader (1974) reviewed evidence for 
the involvement of catecholamines in anxiety and more recently 
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Redmond (1979) summarized considerable evidence for a role 
of norepinephrine in anxiety. 
I~ activation of catecholaminergic system causes anxiety 
then drugs effective in decreasing catecholaminergic trans-
mission should decrease anxiety. The beta-adrenergic recep-
tor blockers, propranolol and oxprenolol have been reported 
to have anxiolytic activity (Jefferson, 1974; Krishman, 1976). 
However, whereas standard anxiolytics are effective against 
both the somatic and psychic components of anxiety, these 
drugs appear to be effective only against the somatic anxiety. 
In the conflict test, Sepinwall et al. (1973) reported pro-
pranolol to be without significant anticonflict effect. 
Recently, Kruse et al. (1980) reported that the presyn-
aptic alpha-adrenergic agonist, clonidine, produced signif i-
cant anticonflict activity in the rat. Furthermore, this ef-
f ect was antagonized by the pre-synaptic alpha-receptor 
blocker (Starke et al., 1975), yohimbine. Several investi-
gators (Holmberg and Gershon, 1961; Ingram, 1962; Gershon 
and Lang, 1962; Garfield et al., 1967) had previously re-
ported that yohimbine produced anxiety in humans. 
To test the hypothesis that the anxiogenic discrimina-
tive stimulus property of PTZ was related to an action of 
increasing catecholaminergic transmission, catecholamine 
agonists were tested for generalization to the PTZ discrimi-
native stimulus and catecholamine antagonists were tested 
for antagonism of the PTZ discriminative stimulus. Of the 
catecholamine agonists tested for generalization only cocaine 
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significantly generalized to the PTZ discriminative stimulus. 
The dopamine receptor agonist, apomorphine, as well as yo-
himbine partially generalized; however, a-amphetamine and 
methylphenidate did not. Propranolol that was previously re-
ported to generalize to the discriminative stimulus property 
of cocaine (Silverman and Ho, 1977), did not generalize to 
the PTZ discriminative stimulus. These data leave it unclear 
whether the anxiogenic discriminative stimulus property of 
PTZ was related to an action of activating catecholaminergic 
mechanisms. However, when several catecholamine antagonists 
including clonidine, aceperone, propranolol, haloperidol or 
chlorpromazine were tested for antagonism of the PTZ dis-
criminative stimulus they were found to be without effect. 
Therefore, these data do not conclusively support the hypo-
thesis that the anxiogenic discriminative stimulus prospects 
of PTZ is related to an effect of increasing catecholaminer-
gic activity. 
7. Endorphins 
The effect of benzodiazepines on endorphins is still 
being worked out. Therefore, the possible involvement of 
these newly discovered endogenous substances in mediating the 
anxiolytic activity of benzodiazepines on anxiety remains to 
be determined. Some of the behavioral effects of benzodiaze-
pines, including their anticonflict effect, however, have 
been reported to be antagonized by the narcotic antagonist, 
naloxone (Billingsly and Kibena, 1978; Gylys et al., 1979). 
--
Thesedata might suggest that anxiolytic activity is mediated 
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by activation of endorphinergic systems. 
To test the hypothesis that the anxiogenic discrimina-
tive stimulus property of PTZ was related to an antagonistic 
effect on endorphin systems, generalization to the PTZ dis-
criminative stimulus with naloxone was tested as was antago-
nism of the PTZ discriminative stimulus with morphine. The 
failure of naloxone to generalize to the PTZ discriminative 
stimulus and the failure of morphine to antagonize this stim-
ulus does not support the hypothesis that the anxiogenic dis-
criminative stimulus property of PTZ is related to an antago-
nistic action on endorphin systems. 
8. Endogenous Benzodiazepine Receptor (Ligand(s) 
The demonstration of saturable, high-affinity, ster-
eospecific benzodiazepine binding sites in the central ner-
vous system (Squires and Braestrup, 1977; Mohler and Okada, 
1977) suggested the presence of endogenous ligands capable 
of regulating the neurophysiological processes subserved by 
these receptors. Several such substances have been sug-
gested as endogenous ligands for benzodiazepine receptors 
(Colello et al., 1978; Karobath et al., 1978; Marangos et 
al., 1978; Skolnick et al., 1978; Mohler et al., 1979; 
Nixon and Wolf, 1979; Skolnick et al., 1979), however, their 
potency is too weak to satisfy a neurotransmitter or neuro-
modulator role. 
Although none of the candidates to date satisfy all the 
criteria for an endogenous ligand of the benzodiazepine 
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receptor, purines and nicotinamide do have benzodiazepine-like 
properties in vivo. Despite the relatively low affinity, 
Skolnick et al. (1979) reported that inosine produced a dose-
and time-related antagonism of PTZ-induced convulsions and 
proposed that endogenously occurring purines such as inosine 
could be naturally occurring ligands for benzodiazepine re-
ceptors. Although the affinity of nicotinamide for the benzo-
diazepine receptor is approximately four to five fold lower 
than affinlties reported for purines (Mohler ~t al., 1979), 
this naturally occurring substance has been reported to par-
tially restore behavior suppressed by punishment in rats. 
Marangos et al. (1979) reported that pentylenetetrazol 
inhibited 3H-diazepam binding in vitro and suggested that PTZ 
may exert pharmacological actions by an interaction with the 
benzodiazepine receptor. Based upon the antagonism of the 
PTZ discriminative stimulus by benzodiazepines it is possible 
that the anxiogenic discriminative stimulus property of PTZ 
is related to its interaction with this receptor. It is pos-
sible that PTZ may exert its angiogenic action by inhibiting 
the binding of a naturally occurring anxiolytic ligand to 
benzodiazepine receptors or mimicking the action of a natural-
ly occurring anxiety-inducing ligand. 
ROS-3663 is structurally related to diazepam, however, 
unlike diazepam it does not bind to benzodiazepine receptors 
(Speth ·et ·a1., 1979; O'Brien and Spirt, 1980). Furthermore, 
whereas diazepam has GABAmimetic activity ROS-3663 antago-
nizes the effect of GABA (Schlosser and Franco, 1979; O'Brien 
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and Spirt, 1980). O'Brien and Spirt (1980) speculated that if 
the anxiolytic action of benzodiazepines were considered to be 
mediat~d through an antagonistic action then a molecule struc-
turally similar to ROS-3663 could exist in brain to function 
as an endogenous anxiety-inducing ligand. 
ROS-3663 dose-dependently generalized to the PTZ discrim-
inative stimulus. Furthermore, the discriminative strength of 
ROS-3663 was attenuated by diazepam. These data provide be-
havioral evidence that ROS-3663 may structurally resemble a 
naturally occurring anxiety-inducing ligand. If this is the 
case PTZ may act by a similar mechanism as this naturally oc-
curring anxiety-inducing ligand. 
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SUMMARY AND CONCLUSIONS 
In summary, it was deITK)nstrated that laboratory rats can 
learn to discriminate between a subconvulsive dose (20 mg/kg) 
of PTZ and saline. A mean of 30 training sessions were re-
quired for the animals to reach the discrimination criterion. 
The discriminative stimulus produced by PTZ was dose- and 
time-dependent. 
The anxiogenic stimulants cocaine, ROS-3663 and strych-
nine generalized to the PTZ discriminative stimulus whereas 
yohimbine partially generalized. The discriminative stimu-
1 us produced by cocaine, ROS-3663 and yohimbine was antago-
nized by diazepam. The discriminative stimulus produced by 
cocaine was not antagonized by haloperidol. The non-anxio-
genic psychomotor stimulants a-amphetamine, methylphenidate 
and caffeine did not generalize to the PTZ discriminative 
stimulus. These data support the hypothesis that the dis-
criminative stimulus produced by PTZ in the rat is related 
to its anxiogenic action in man. 
Of the several convulsant drugs tested, only bemegride 
significnatly generalized to the PTZ discriminative stimulus 
whereas picrotoxin and 3-mercaptopropionic acid partially 
generalized. Bicuculline, nicotine or gamrna-hydroxybutyrate 
did not generalize to the PTZ discriminative stimulus. These 
data suggest that the PTZ discriminative stimulus is probably 
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not relate<l to a subconvulsant brain state likely to be pro-
duced by these drugs. 
Tpe PTZ discriminative stimulus was dose-dependently an-
tagonized by benzodiazepine-type, barbiturate-type and pro-
panediol carbamate-type anxiolytics as well as valproic acid. 
Because tolerance develops to the sedative but not anxiolytic 
benzodiazepines, lack of tolerance development to diazepam 
or chlordiazepoxide in antagonism of the PTZ discriminative 
stimulus suggests that this property w&s related to their 
anxiolytic action. 
There was a significant correlation between the potency 
of the drugs effective in antagonizing the PTZ discrimina-
tive stimulus and their effective doses in a conflict test 
used to measure anxiolytic activity as well as their clini-
cally effective doses. 
The PTZ discriminative stimulus was not antagonized by 
the nonanxiolytic anticonvulsants ethosuximide, etomidate, 
trimethadone or diphenylhydantoin nor the nonanxiolytic cen-
tral nervous system depressants morphine, ethanol, chlor-
prornazine, or haloperidol. These data suggest that the PTZ 
discriminative stimulus is not related to a subconvulsant 
brain state or nonspecific central nervous system stimula-
tion. 
The GABA antagonist, ROS-3663, dose-dependently general-
ized to the PTZ discriminative stimulus, whereas picrotoxin 
and 3-mercaptopropionic acid partially generalized. The 
GABAmimetic drug, valproic acid, antagonized the PTZ dis-
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crirninative stimulus. These data suggest that the PTZ dis-
criminative stimulus might be mediated through decreased GABA 
neuronal activity. Because of the known GABA ·mimetic pro-
perty of benzodiazepines it was suggested that antagonism of 
the PTZ discriminative stimulus by these drugs may be related 
to their effect on GABA transmission. 
The glycine antagonist, strychnine, generalized to the 
PTZ discriminative stimulus suggesting the possible involve-
ment of decreased glycinergic activity for the discriminative 
stimulus property of PTZ. However, in view of the consider-
able evidence for the involvement of GABA and the lack of ef-
fect of PTZ on glycine in vitro it was suggested that general 
interference with inhibitory transmission -may generate a dis-
criminative stimulus like that produced by PTZ. 
Drugs affecting acetylcholine or serotonin systems did 
not generalize to or antagonize the PTZ discriminative stim-
ulus. These data suggested that the PTZ discriminative 
stimulus was not related to an effect on these neurotrans-
mitter systems. 
Cocaine generalized to the PTZ discriminative stimulus 
whereas yohimbine and apomorphine partially generalized. 
The PTZ discriminative stimulus was not blocked by drugs 
with anti-catecholaminergic activity. Therefore these data 
do not support the involvement of catecholamine mechanisms 
for the discriminative stimulus property of PTZ. 
In view of the recent demonstration of benzodiazepine 
receptors in brain, it was suggested that PTZ may produce 
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its anxiogenic action by interacting with an unknown ligand 
for the benzodiazepine receptor. PTZ may either mimic a natur-
ally o?curring anxiety-inducing ligand or inhibit the action 
of a naturally occurring anxiolytic ligand. 
In conclusion the data presented in this dissertation 
support the hypothesis that the discriminative stimulus pro-
perty of PTZ in the rat is related to its anxiogenic action in 
man. It is suggested that the anxiogenic stimulus produced 
by PTZ is related to deficits in GABA neuronal activity. 
Tedeschi (1969) suggested that for animal tests to have 
predictive value as models for a particular human condition, 
they must fulfill the following criteria: 
1. Tests should be selective enough to differentiate 
false positives, and to distinguish side effects from thera-
peutic activity. 
2. Tests should be sensitive enough to detect activity 
of reference agents within a reasonable dose range. 
3. The relative potency of reference agents in the 
animal test should compare with their relative potency in man. 
4. Tolerance should not develop to the measure presumed 
to reflect therapeutic efficacy. 
The PTZ-saline discrimination paradigm described in this 
dissertation fulfills all of these criteria. Therefore it 
is suggested that this procedure may represent a new animal 
model of anxiety that can be used to detect anxiolytic activ-
ity of new compounds. 
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Currently, prevention of PTZ-induced seizures is used as 
a screening test for anxiolytic drugs. However, all of the 
drugs that prevent these seizures are not anxiolytics. To 
date there have been no false positives in the PTZ-saline dis-
crimination procedure. All of the drugs that antagonize the 
PTZ discriminative stimulus are clinically effective anxio-
lytics. Currently, there is no animal model to detect anxio-
genic side effects of drugs; the PTZ-saline discrimination 
may provide such a model. 
In addition to these potential benefits for drug develop-
ment, the PTZ-saline discrimination may be used to investi-
gate the neurochemical mechanisms and behavioral factors re-
lated to anxiety as well as the mechanism of action of anxio-
lytic drugs. It is the author's hope that the work reported 
in this dissertation will contribute towards these ends. 
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